Ignite Creation Date:
2025-12-26 @ 5:21 PM
Ignite Modification Date:
2026-03-05 @ 12:47 PM
Study NCT ID:
NCT02905006
Status:
COMPLETED
Last Update Posted:
2022-07-21
First Post:
2016-09-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011565', 'term': 'Psoriasis'}], 'ancestors': [{'id': 'D017444', 'term': 'Skin Diseases, Papulosquamous'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000625981', 'term': 'bimekizumab'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'UCBCares@ucb.com', 'phone': '+1877 822', 'title': 'UCB', 'phoneExt': '9493', 'organization': 'Cares'}, 'certainAgreement': {'restrictionType': 'GT60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Treatment-emergent adverse events (TEAEs) were collected from Baseline (Week 0) to End of Safety Follow-up (up to Week 28)', 'description': 'It was pre-specified to report adverse events (AE) that have a start date on or following the first administration of study treatment. TEAEs counts are for each study period: Treatment Period (Wk1-12) for all participants who received at least 1 study treatment and Post-Treatment Period for participants who either enrolled in an extension study (PS0011) or those who entered a 20-week Safety Follow-Up Period.', 'eventGroups': [{'id': 'EG000', 'title': 'Placebo (SS) Treatment Period', 'description': 'During the Treatment Period participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).', 'otherNumAtRisk': 42, 'deathsNumAtRisk': 42, 'otherNumAffected': 8, 'seriousNumAtRisk': 42, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Bimekizumab 64 mg Q4W (SS) Treatment Period', 'description': 'During the Treatment Period participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.', 'otherNumAtRisk': 39, 'deathsNumAtRisk': 39, 'otherNumAffected': 16, 'seriousNumAtRisk': 39, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'Bimekizumab 160 mg Q4W (SS) Treatment Period', 'description': 'During the Treatment Period participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.', 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 12, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS) Treatment Period', 'description': 'During the Treatment Period participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.', 'otherNumAtRisk': 40, 'deathsNumAtRisk': 40, 'otherNumAffected': 12, 'seriousNumAtRisk': 40, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG004', 'title': 'Bimekizumab 320 mg Q4W (SS) Treatment Period', 'description': 'During the Treatment Period participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.', 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 14, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG005', 'title': 'Bimekizumab 480 mg Q4W (SS) Treatment Period', 'description': 'During the Treatment Period participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.', 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 10, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG006', 'title': 'Placebo (SS) Post-Treatment Period', 'description': 'At Week 12, participants who were randomized to receive Placebo during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.\n\nParticipants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.', 'otherNumAtRisk': 42, 'deathsNumAtRisk': 42, 'otherNumAffected': 0, 'seriousNumAtRisk': 42, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG007', 'title': 'Bimekizumab 64 mg Q4W (SS) Post-Treatment Period', 'description': 'At Week 12, participants who were randomized to receive 64 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.\n\nParticipants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.', 'otherNumAtRisk': 39, 'deathsNumAtRisk': 39, 'otherNumAffected': 0, 'seriousNumAtRisk': 39, 'deathsNumAffected': 0, 'seriousNumAffected': 1}, {'id': 'EG008', 'title': 'Bimekizumab 160 mg Q4W (SS) Post-Treatment Period', 'description': 'At Week 12, participants who were randomized to receive 160 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.\n\nParticipants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.', 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 0, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG009', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS) Post-Treatment Period', 'description': 'At Week 12, participants who were randomized to receive 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.\n\nParticipants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.', 'otherNumAtRisk': 40, 'deathsNumAtRisk': 40, 'otherNumAffected': 0, 'seriousNumAtRisk': 40, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG010', 'title': 'Bimekizumab 320 mg Q4W (SS) Post-Treatment Period', 'description': 'At Week 12, participants who were randomized to receive 320 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.\n\nParticipants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.', 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 0, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG011', 'title': 'Bimekizumab 480 mg Q4W (SS) Post-Treatment Period', 'description': 'At Week 12, participants who were randomized to receive 480 mg bimekizumab Q4W during the Treatment Period and who enrolled in the extension study (PS0011), underwent the Week 12 study assessments and then received their first extension study dose of study treatment. All participants who did not enroll in the extension study had the Week 12 study assessments and entered the Safety Follow-Up (SFU) Period, 20 weeks after the last dose of study medication.\n\nParticipants did not receive any treatment during the Post-Treatment Period. Participants formed the SS.', 'otherNumAtRisk': 43, 'deathsNumAtRisk': 43, 'otherNumAffected': 0, 'seriousNumAtRisk': 43, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Tonsillitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Oral candidiasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Rhinitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Gamma-glutamyltransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 3, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 5, 'numAffected': 3}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}], 'seriousEvents': [{'term': 'Large intestine polyp', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Meningitis viral', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Colon cancer', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}, {'term': 'Myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 39, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG006', 'numAtRisk': 42, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG007', 'numAtRisk': 39, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG008', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG009', 'numAtRisk': 40, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG010', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG011', 'numAtRisk': 43, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA19.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (FAS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '46.2', 'groupId': 'OG001'}, {'value': '67.4', 'groupId': 'OG002'}, {'value': '75.0', 'groupId': 'OG003'}, {'value': '79.1', 'groupId': 'OG004'}, {'value': '72.1', 'groupId': 'OG005'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'pValueComment': 'P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'pValueComment': 'P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'pValueComment': 'P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG005'], 'pValueComment': 'P-value evaluating dose response excludes the BKZ Dose 3 group; is based on a logistic regression model with fixed effects for region, prior biologic exposure, continuous treatment variable with values of -2, -1, 0, 1, 2 for the remaining groups.', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': "The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 12", 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (FAS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.8', 'groupId': 'OG000'}, {'value': '51.3', 'groupId': 'OG001'}, {'value': '74.4', 'groupId': 'OG002'}, {'value': '75.0', 'groupId': 'OG003'}, {'value': '86.0', 'groupId': 'OG004'}, {'value': '76.7', 'groupId': 'OG005'}]}]}], 'analyses': [{'pValue': '=0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '21.43', 'ciLowerLimit': '4.51', 'ciUpperLimit': '101.88', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '63.21', 'ciLowerLimit': '12.90', 'ciUpperLimit': '309.83', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '62.35', 'ciLowerLimit': '12.61', 'ciUpperLimit': '308.29', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '130.35', 'ciLowerLimit': '24.50', 'ciUpperLimit': '693.51', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG005'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '69.40', 'ciLowerLimit': '14.07', 'ciUpperLimit': '342.40', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': "The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.'}, {'type': 'SECONDARY', 'title': "Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 8", 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (FAS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.8', 'groupId': 'OG000'}, {'value': '46.2', 'groupId': 'OG001'}, {'value': '62.8', 'groupId': 'OG002'}, {'value': '77.5', 'groupId': 'OG003'}, {'value': '86.0', 'groupId': 'OG004'}, {'value': '72.1', 'groupId': 'OG005'}]}]}], 'analyses': [{'pValue': '=0.0003', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '18.23', 'ciLowerLimit': '3.79', 'ciUpperLimit': '87.76', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '39.60', 'ciLowerLimit': '8.19', 'ciUpperLimit': '191.59', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '77.27', 'ciLowerLimit': '15.19', 'ciUpperLimit': '392.93', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '141.99', 'ciLowerLimit': '26.26', 'ciUpperLimit': '767.72', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG005'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '58.52', 'ciLowerLimit': '11.89', 'ciUpperLimit': '288.00', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 8', 'description': "The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (FAS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '41.0', 'groupId': 'OG001'}, {'value': '58.1', 'groupId': 'OG002'}, {'value': '67.5', 'groupId': 'OG003'}, {'value': '86.0', 'groupId': 'OG004'}, {'value': '69.8', 'groupId': 'OG005'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'pValueComment': "The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'pValueComment': "The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'pValueComment': "The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'pValueComment': "The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG005'], 'pValueComment': "The placebo treatment group contained no PASI90 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 8', 'description': "The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (FAS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.8', 'groupId': 'OG000'}, {'value': '61.5', 'groupId': 'OG001'}, {'value': '81.4', 'groupId': 'OG002'}, {'value': '85.0', 'groupId': 'OG003'}, {'value': '93.0', 'groupId': 'OG004'}, {'value': '83.7', 'groupId': 'OG005'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '32.65', 'ciLowerLimit': '6.82', 'ciUpperLimit': '156.38', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG002'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '94.51', 'ciLowerLimit': '18.54', 'ciUpperLimit': '481.86', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '117.66', 'ciLowerLimit': '22.08', 'ciUpperLimit': '626.89', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '280.76', 'ciLowerLimit': '44.06', 'ciUpperLimit': '1789.24', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG005'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '107.83', 'ciLowerLimit': '20.82', 'ciUpperLimit': '558.57', 'statisticalMethod': 'Regression, Logistic', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Confidence intervals, odds ratios, p-values derived from a logistic regression model with fixed effects for treatment, region, prior bio-exposure.'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': "The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving a 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (FAS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Full Analysis Set (FAS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the FAS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (FAS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the FAS.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '28.2', 'groupId': 'OG001'}, {'value': '27.9', 'groupId': 'OG002'}, {'value': '60.0', 'groupId': 'OG003'}, {'value': '55.8', 'groupId': 'OG004'}, {'value': '48.8', 'groupId': 'OG005'}]}]}], 'analyses': [{'pValue': '=0.0001', 'groupIds': ['OG000', 'OG001'], 'groupDescription': "The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '=0.0002', 'groupIds': ['OG000', 'OG002'], 'groupDescription': "The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG003'], 'groupDescription': "The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG004'], 'groupDescription': "The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}, {'pValue': '<0.0001', 'groupIds': ['OG000', 'OG005'], 'groupDescription': "The placebo treatment group contained no PASI100 responders and as such the p-values for the pairwise comparisons are based upon the Fisher's exact test.", 'statisticalMethod': 'Fisher Exact', 'nonInferiorityType': 'SUPERIORITY'}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': "PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72. The PASI 100 response rate at Week 12 is measured as the percentage of participants who achieved 100% improvement from baseline PASI at Week 12.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Full Analysis Set (FAS) consisted of all randomized participants who received at least 1 dose of the study medication and had a valid measurement of the primary efficacy variable at Baseline.'}, {'type': 'SECONDARY', 'title': 'Plasma Concentrations of Bimekizumab During the Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '43', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Bimekizumab 64 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG001', 'title': 'Bimekizumab 160 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg w/ LD Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG003', 'title': 'Bimekizumab 320 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG004', 'title': 'Bimekizumab 480 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the PK-PPS.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '43', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Values were below the level of detection; Participants had no prior BKZ treatment.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Values were below the level of detection; Participants had no prior BKZ treatment.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Values were below the level of detection; Participants had no prior BKZ treatment.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Values were below the level of detection; Participants had no prior BKZ treatment.', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Values were below the level of detection; Participants had no prior BKZ treatment.', 'groupId': 'OG004', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}, {'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '42', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '43', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '4.4490', 'groupId': 'OG000', 'lowerLimit': '3.7526', 'upperLimit': '5.2746'}, {'value': '9.2481', 'groupId': 'OG001', 'lowerLimit': '6.9779', 'upperLimit': '12.2569'}, {'value': '20.7892', 'groupId': 'OG002', 'lowerLimit': '14.9192', 'upperLimit': '28.9688'}, {'value': '21.8622', 'groupId': 'OG003', 'lowerLimit': '16.0624', 'upperLimit': '29.7563'}, {'value': '31.8019', 'groupId': 'OG004', 'lowerLimit': '23.3488', 'upperLimit': '43.3154'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '41', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '3.4704', 'groupId': 'OG000', 'lowerLimit': '3.0167', 'upperLimit': '3.9923'}, {'value': '8.6862', 'groupId': 'OG001', 'lowerLimit': '7.5316', 'upperLimit': '10.0179'}, {'value': '19.0428', 'groupId': 'OG002', 'lowerLimit': '16.5381', 'upperLimit': '21.9267'}, {'value': '19.0324', 'groupId': 'OG003', 'lowerLimit': '16.8925', 'upperLimit': '21.4434'}, {'value': '27.5641', 'groupId': 'OG004', 'lowerLimit': '23.8485', 'upperLimit': '31.8586'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '41', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}, {'value': '41', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '2.1282', 'groupId': 'OG000', 'lowerLimit': '1.8398', 'upperLimit': '2.4617'}, {'value': '5.3751', 'groupId': 'OG001', 'lowerLimit': '4.5233', 'upperLimit': '6.3872'}, {'value': '11.2903', 'groupId': 'OG002', 'lowerLimit': '9.4809', 'upperLimit': '13.4450'}, {'value': '11.9194', 'groupId': 'OG003', 'lowerLimit': '10.4503', 'upperLimit': '13.5951'}, {'value': '17.1811', 'groupId': 'OG004', 'lowerLimit': '14.7612', 'upperLimit': '19.9977'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '2.3069', 'groupId': 'OG000', 'lowerLimit': '1.7780', 'upperLimit': '2.9931'}, {'value': '7.1859', 'groupId': 'OG001', 'lowerLimit': '5.3747', 'upperLimit': '9.6075'}, {'value': '10.2208', 'groupId': 'OG002', 'lowerLimit': '8.8561', 'upperLimit': '11.7957'}, {'value': '16.3187', 'groupId': 'OG003', 'lowerLimit': '13.9947', 'upperLimit': '19.0285'}, {'value': '23.3285', 'groupId': 'OG004', 'lowerLimit': '19.8863', 'upperLimit': '27.3665'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': '2.3121', 'groupId': 'OG000', 'lowerLimit': '1.6037', 'upperLimit': '3.3335'}, {'value': '9.5278', 'groupId': 'OG001', 'lowerLimit': '8.0614', 'upperLimit': '11.2608'}, {'value': '10.2557', 'groupId': 'OG002', 'lowerLimit': '8.6807', 'upperLimit': '12.1165'}, {'value': '18.3166', 'groupId': 'OG003', 'lowerLimit': '15.1652', 'upperLimit': '22.1228'}, {'value': '28.0908', 'groupId': 'OG004', 'lowerLimit': '23.2463', 'upperLimit': '33.9448'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '1', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}]}], 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Values were below the level of detection.', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Values were below the level of detection.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Values were below the level of detection.', 'groupId': 'OG002', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': 'NA', 'comment': 'Values were below the level of detection.', 'groupId': 'OG003', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '0.5165', 'groupId': 'OG004', 'lowerLimit': '0.0032', 'upperLimit': '84.5222'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Bimekizumab plasma concentration was expressed in micrograms per milliliter (μg/mL).\n\nValues Below Limit of Quantification (BLQ) were replaced by the value of lower limit of quantification (LLOQ) divided by 2 = 0.075 μg/mL in the calculations of geometric mean and confidence intervals (CIs). Geometric mean was only calculated if at least two-thirds of the concentrations were quantified at the respective time point.', 'unitOfMeasure': 'µg/mL', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.'}, {'type': 'SECONDARY', 'title': 'Population PK (Apparent Total Clearance (CL/F)) of Bimekizumab', 'denoms': [{'units': 'Participants', 'counts': [{'value': '249', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'All Participants (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of placebo or bimekizumab in different dosages: 64 mg Q4W, 160 mg Q4W, 320 mg loading dose at Baseline followed by 160 mg Q4W, 320 mg Q4W, 480 mg Q4W during the 12-week Treatment Period. Participants formed the PK-PPS.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.362', 'spread': '41.7', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)', 'description': 'The data were presented as population estimates of CL/F. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.\n\nIt was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.', 'unitOfMeasure': 'L/Day', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.'}, {'type': 'SECONDARY', 'title': 'Population PK (Apparent Volume of Distribution (V/F)) of Bimekizumab', 'denoms': [{'units': 'Participants', 'counts': [{'value': '249', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'All Participants (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of placebo or bimekizumab in different dosages: 64 mg Q4W, 160 mg Q4W, 320 mg loading dose at Baseline followed by 160 mg Q4W, 320 mg Q4W, 480 mg Q4W during the 12-week Treatment Period. Participants formed the PK-PPS.'}], 'classes': [{'categories': [{'measurements': [{'value': '11.5', 'spread': '146', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)', 'description': 'The data were presented as population estimates of V/F. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.\n\nIt was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.', 'unitOfMeasure': 'liters', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.'}, {'type': 'SECONDARY', 'title': 'Concentration of Bimekizumab Leading to 50% of Maximum Effect (EC50)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '249', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'All Participants (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of placebo or bimekizumab in different dosages: 64 mg Q4W, 160 mg Q4W, 320 mg loading dose at Baseline followed by 160 mg Q4W, 320 mg Q4W, 480 mg Q4W during the 12-week Treatment Period. Participants formed the PK-PPS.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.55', 'spread': '126', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)', 'description': 'The data were presented as population estimates of EC50. EC50 was estimated based on all available data and cannot be derived for each treatment arm.\n\nIt was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.', 'unitOfMeasure': 'µg/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PK-PPS consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables. EC50 was estimated based on all available data and cannot be derived for each treatment arm.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With a Positive Anti-bimekizumab Antibody (AbAb) Status Prior to Study Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (PK-PPS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Pharmacokinetics Per-Protocol Set (PK-PPS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the PK-PPS.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2.5', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline (Week 0)', 'description': 'Antibody positive status prior study treatment was defined as having an antibody level greater than (\\>) 28.5% at Baseline (Week 0).', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With an Overall Positive Anti-bimekizumab Antibody (AbAb) Status Following Study Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (PK-PPS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Pharmacokinetics Per-Protocol Set (PK-PPS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the PK-PPS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (PK-PPS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the PK-PPS.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '10.3', 'groupId': 'OG001'}, {'value': '4.8', 'groupId': 'OG002'}, {'value': '5.0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Week 4 until the Safety Follow-Up visit (20 weeks after the last dose; Up to Week 28)', 'description': 'Overall antibody positive was defined as having a value of \\> 28.5% at any time in the Treatment Period. The Treatment Period did not include Baseline/pretreatment samples.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Pharmacokinetics Per-Protocol Set (PK-PPS) consisted of all randomized participants who took at least 1 dose of the IMP and provided at least 1 quantifiable plasma concentration postdose and had no important protocol deviations affecting the PK variables.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With at Least One Adverse Event (AE) During the Study', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'categories': [{'measurements': [{'value': '38.1', 'groupId': 'OG000'}, {'value': '76.9', 'groupId': 'OG001'}, {'value': '55.8', 'groupId': 'OG002'}, {'value': '65.0', 'groupId': 'OG003'}, {'value': '60.5', 'groupId': 'OG004'}, {'value': '60.5', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Screening to End of Safety Follow-up (up to Week 32)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With at Least One Adverse Event (AE) During the Study by Severity', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Mild', 'categories': [{'measurements': [{'value': '11.9', 'groupId': 'OG000'}, {'value': '43.6', 'groupId': 'OG001'}, {'value': '27.9', 'groupId': 'OG002'}, {'value': '22.5', 'groupId': 'OG003'}, {'value': '39.5', 'groupId': 'OG004'}, {'value': '44.2', 'groupId': 'OG005'}]}]}, {'title': 'Moderate', 'categories': [{'measurements': [{'value': '26.2', 'groupId': 'OG000'}, {'value': '30.8', 'groupId': 'OG001'}, {'value': '27.9', 'groupId': 'OG002'}, {'value': '40.0', 'groupId': 'OG003'}, {'value': '20.9', 'groupId': 'OG004'}, {'value': '11.6', 'groupId': 'OG005'}]}]}, {'title': 'Severe', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2.6', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2.5', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '4.7', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Screening to End of Safety Follow-up (up to Week 32)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '12.1', 'spread': '34.7', 'groupId': 'OG000'}, {'value': '3.2', 'spread': '21.0', 'groupId': 'OG001'}, {'value': '-4.6', 'spread': '30.8', 'groupId': 'OG002'}, {'value': '-14.0', 'spread': '30.8', 'groupId': 'OG003'}, {'value': '3.5', 'spread': '25.2', 'groupId': 'OG004'}, {'value': '-0.1', 'spread': '35.0', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '40', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '6.4', 'spread': '37.8', 'groupId': 'OG000'}, {'value': '-8.6', 'spread': '26.8', 'groupId': 'OG001'}, {'value': '-5.6', 'spread': '36.4', 'groupId': 'OG002'}, {'value': '-8.9', 'spread': '27.8', 'groupId': 'OG003'}, {'value': '7.8', 'spread': '31.2', 'groupId': 'OG004'}, {'value': '-3.9', 'spread': '41.8', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '32.0', 'groupId': 'OG000'}, {'value': '-5.8', 'spread': '28.3', 'groupId': 'OG001'}, {'value': '-8.6', 'spread': '40.1', 'groupId': 'OG002'}, {'value': '-11.4', 'spread': '21.8', 'groupId': 'OG003'}, {'value': '-7.0', 'spread': '28.9', 'groupId': 'OG004'}, {'value': '-7.5', 'spread': '36.8', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '5.6', 'spread': '47.5', 'groupId': 'OG000'}, {'value': '-5.2', 'spread': '26.3', 'groupId': 'OG001'}, {'value': '-13.6', 'spread': '34.3', 'groupId': 'OG002'}, {'value': '-5.6', 'spread': '30.3', 'groupId': 'OG003'}, {'value': '-0.3', 'spread': '44.0', 'groupId': 'OG004'}, {'value': '-7.6', 'spread': '37.3', 'groupId': 'OG005'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '6.9', 'spread': '37.6', 'groupId': 'OG000'}, {'value': '-2.3', 'spread': '44.7', 'groupId': 'OG001'}, {'value': '-6.1', 'spread': '43.7', 'groupId': 'OG002'}, {'value': '6.3', 'spread': '35.6', 'groupId': 'OG003'}, {'value': '0.7', 'spread': '39.5', 'groupId': 'OG004'}, {'value': '-4.7', 'spread': '36.4', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '2.8', 'spread': '36.7', 'groupId': 'OG000'}, {'value': '-6.0', 'spread': '36.2', 'groupId': 'OG001'}, {'value': '-13.2', 'spread': '40.1', 'groupId': 'OG002'}, {'value': '-3.6', 'spread': '37.5', 'groupId': 'OG003'}, {'value': '-5.4', 'spread': '36.1', 'groupId': 'OG004'}, {'value': '-5.5', 'spread': '38.8', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '14.8', 'spread': '33.3', 'groupId': 'OG000'}, {'value': '-30.3', 'spread': '71.6', 'groupId': 'OG001'}, {'value': '7.8', 'spread': '20.0', 'groupId': 'OG002'}, {'value': '-33.0', 'spread': '31.1', 'groupId': 'OG003'}, {'value': '39.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '39.3', 'spread': '27.4', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Platelets was measured in number of platelets per liter (10\\^9/L).', 'unitOfMeasure': '10^9 platelets per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Ery. mean corpuscular HGB Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '8.1', 'groupId': 'OG000'}, {'value': '-2.0', 'spread': '10.3', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '8.8', 'groupId': 'OG002'}, {'value': '-1.0', 'spread': '11.6', 'groupId': 'OG003'}, {'value': '0.5', 'spread': '8.6', 'groupId': 'OG004'}, {'value': '0.3', 'spread': '8.1', 'groupId': 'OG005'}]}]}, {'title': 'Ery. mean corpuscular HGB Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '7.9', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '6.6', 'groupId': 'OG001'}, {'value': '1.6', 'spread': '9.4', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '9.8', 'groupId': 'OG003'}, {'value': '2.6', 'spread': '7.9', 'groupId': 'OG004'}, {'value': '1.8', 'spread': '8.8', 'groupId': 'OG005'}]}]}, {'title': 'Ery. mean corpuscular HGB Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '9.1', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '8.3', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '9.9', 'groupId': 'OG002'}, {'value': '-2.9', 'spread': '6.3', 'groupId': 'OG003'}, {'value': '0.1', 'spread': '8.0', 'groupId': 'OG004'}, {'value': '-0.4', 'spread': '11.7', 'groupId': 'OG005'}]}]}, {'title': 'Ery. mean corpuscular HGB Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.5', 'spread': '11.0', 'groupId': 'OG000'}, {'value': '-1.7', 'spread': '8.6', 'groupId': 'OG001'}, {'value': '-0.5', 'spread': '9.4', 'groupId': 'OG002'}, {'value': '-2.9', 'spread': '7.0', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '7.8', 'groupId': 'OG004'}, {'value': '-1.3', 'spread': '8.9', 'groupId': 'OG005'}]}]}, {'title': 'Ery. mean corpuscular HGB Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.2', 'spread': '8.0', 'groupId': 'OG000'}, {'value': '-1.4', 'spread': '12.7', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '10.3', 'groupId': 'OG002'}, {'value': '-2.5', 'spread': '7.9', 'groupId': 'OG003'}, {'value': '-2.1', 'spread': '9.2', 'groupId': 'OG004'}, {'value': '-2.9', 'spread': '9.2', 'groupId': 'OG005'}]}]}, {'title': 'Ery. mean corpuscular HGB Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-6.3', 'spread': '12.5', 'groupId': 'OG000'}, {'value': '-2.2', 'spread': '14.7', 'groupId': 'OG001'}, {'value': '-1.6', 'spread': '9.1', 'groupId': 'OG002'}, {'value': '-4.5', 'spread': '10.1', 'groupId': 'OG003'}, {'value': '-2.0', 'spread': '12.7', 'groupId': 'OG004'}, {'value': '-3.6', 'spread': '13.7', 'groupId': 'OG005'}]}]}, {'title': 'Ery. mean corpuscular HGB SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-12.5', 'spread': '11.0', 'groupId': 'OG000'}, {'value': '5.3', 'spread': '26.2', 'groupId': 'OG001'}, {'value': '-5.5', 'spread': '10.6', 'groupId': 'OG002'}, {'value': '-9.5', 'spread': '7.8', 'groupId': 'OG003'}, {'value': '-2.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-22.0', 'spread': '18.0', 'groupId': 'OG005'}]}]}, {'title': 'Hemoglobin Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '7.3', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '6.1', 'groupId': 'OG001'}, {'value': '1.0', 'spread': '6.8', 'groupId': 'OG002'}, {'value': '-2.6', 'spread': '5.2', 'groupId': 'OG003'}, {'value': '-1.0', 'spread': '7.0', 'groupId': 'OG004'}, {'value': '-0.8', 'spread': '5.0', 'groupId': 'OG005'}]}]}, {'title': 'Hemoglobin Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-3.0', 'spread': '6.7', 'groupId': 'OG000'}, {'value': '0.5', 'spread': '5.3', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '6.0', 'groupId': 'OG002'}, {'value': '-1.5', 'spread': '7.5', 'groupId': 'OG003'}, {'value': '-1.1', 'spread': '7.0', 'groupId': 'OG004'}, {'value': '0.5', 'spread': '6.6', 'groupId': 'OG005'}]}]}, {'title': 'Hemoglobin Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.9', 'spread': '8.2', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '6.1', 'groupId': 'OG001'}, {'value': '-0.9', 'spread': '6.2', 'groupId': 'OG002'}, {'value': '-2.1', 'spread': '5.9', 'groupId': 'OG003'}, {'value': '-1.8', 'spread': '8.7', 'groupId': 'OG004'}, {'value': '-0.4', 'spread': '6.3', 'groupId': 'OG005'}]}]}, {'title': 'Hemoglobin Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '7.8', 'groupId': 'OG000'}, {'value': '0.7', 'spread': '6.3', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '6.6', 'groupId': 'OG002'}, {'value': '-1.2', 'spread': '4.8', 'groupId': 'OG003'}, {'value': '-2.1', 'spread': '8.4', 'groupId': 'OG004'}, {'value': '0.9', 'spread': '6.3', 'groupId': 'OG005'}]}]}, {'title': 'Hemoglobin Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.7', 'spread': '8.0', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '7.6', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '7.1', 'groupId': 'OG002'}, {'value': '-0.6', 'spread': '7.5', 'groupId': 'OG003'}, {'value': '-1.8', 'spread': '8.1', 'groupId': 'OG004'}, {'value': '0.9', 'spread': '6.5', 'groupId': 'OG005'}]}]}, {'title': 'Hemoglobin Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '9.1', 'groupId': 'OG000'}, {'value': '3.2', 'spread': '9.6', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '8.1', 'groupId': 'OG002'}, {'value': '-1.0', 'spread': '8.5', 'groupId': 'OG003'}, {'value': '-1.2', 'spread': '9.3', 'groupId': 'OG004'}, {'value': '0.3', 'spread': '7.1', 'groupId': 'OG005'}]}]}, {'title': 'Hemoglobin SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-4.8', 'spread': '7.4', 'groupId': 'OG000'}, {'value': '7.8', 'spread': '31.0', 'groupId': 'OG001'}, {'value': '-6.5', 'spread': '4.7', 'groupId': 'OG002'}, {'value': '-8.5', 'spread': '2.1', 'groupId': 'OG003'}, {'value': '6.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-6.7', 'spread': '11.0', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Erythrocytes mean corpuscular hemoglobin (HGB) concentration and hemoglobin were measured in grams per liter (g/L).', 'unitOfMeasure': 'g/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.57', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.56', 'groupId': 'OG001'}, {'value': '-0.10', 'spread': '0.55', 'groupId': 'OG002'}, {'value': '0.07', 'spread': '0.51', 'groupId': 'OG003'}, {'value': '-0.09', 'spread': '0.87', 'groupId': 'OG004'}, {'value': '0.00', 'spread': '0.53', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.59', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.54', 'groupId': 'OG001'}, {'value': '0.05', 'spread': '0.49', 'groupId': 'OG002'}, {'value': '0.10', 'spread': '0.78', 'groupId': 'OG003'}, {'value': '-0.03', 'spread': '0.60', 'groupId': 'OG004'}, {'value': '0.14', 'spread': '0.54', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.66', 'groupId': 'OG000'}, {'value': '0.10', 'spread': '0.84', 'groupId': 'OG001'}, {'value': '-0.07', 'spread': '0.63', 'groupId': 'OG002'}, {'value': '-0.01', 'spread': '0.42', 'groupId': 'OG003'}, {'value': '-0.10', 'spread': '0.68', 'groupId': 'OG004'}, {'value': '0.04', 'spread': '0.50', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.17', 'spread': '0.64', 'groupId': 'OG000'}, {'value': '-0.09', 'spread': '0.84', 'groupId': 'OG001'}, {'value': '-0.16', 'spread': '0.61', 'groupId': 'OG002'}, {'value': '-0.11', 'spread': '0.47', 'groupId': 'OG003'}, {'value': '-0.12', 'spread': '0.84', 'groupId': 'OG004'}, {'value': '-0.04', 'spread': '0.60', 'groupId': 'OG005'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.19', 'spread': '0.64', 'groupId': 'OG000'}, {'value': '0.09', 'spread': '1.09', 'groupId': 'OG001'}, {'value': '-0.16', 'spread': '1.10', 'groupId': 'OG002'}, {'value': '-0.16', 'spread': '0.64', 'groupId': 'OG003'}, {'value': '-0.26', 'spread': '0.99', 'groupId': 'OG004'}, {'value': '-0.16', 'spread': '0.53', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.34', 'spread': '0.71', 'groupId': 'OG000'}, {'value': '0.09', 'spread': '1.53', 'groupId': 'OG001'}, {'value': '-0.08', 'spread': '0.58', 'groupId': 'OG002'}, {'value': '-0.14', 'spread': '0.66', 'groupId': 'OG003'}, {'value': '-0.09', 'spread': '1.14', 'groupId': 'OG004'}, {'value': '-0.16', 'spread': '0.67', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.33', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '2.93', 'spread': '6.66', 'groupId': 'OG001'}, {'value': '-0.15', 'spread': '0.17', 'groupId': 'OG002'}, {'value': '-0.55', 'spread': '0.78', 'groupId': 'OG003'}, {'value': '0.70', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-0.60', 'spread': '1.10', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).', 'unitOfMeasure': 'picograms (pg)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.35', 'spread': '1.55', 'groupId': 'OG000'}, {'value': '0.52', 'spread': '2.29', 'groupId': 'OG001'}, {'value': '-0.25', 'spread': '1.64', 'groupId': 'OG002'}, {'value': '0.51', 'spread': '2.63', 'groupId': 'OG003'}, {'value': '-0.23', 'spread': '2.14', 'groupId': 'OG004'}, {'value': '-0.04', 'spread': '1.37', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.14', 'spread': '1.65', 'groupId': 'OG000'}, {'value': '-0.16', 'spread': '1.31', 'groupId': 'OG001'}, {'value': '-0.33', 'spread': '1.96', 'groupId': 'OG002'}, {'value': '0.31', 'spread': '1.32', 'groupId': 'OG003'}, {'value': '-0.64', 'spread': '1.40', 'groupId': 'OG004'}, {'value': '-0.05', 'spread': '1.60', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '1.60', 'groupId': 'OG000'}, {'value': '0.23', 'spread': '1.89', 'groupId': 'OG001'}, {'value': '-0.25', 'spread': '1.81', 'groupId': 'OG002'}, {'value': '0.67', 'spread': '1.76', 'groupId': 'OG003'}, {'value': '-0.10', 'spread': '1.64', 'groupId': 'OG004'}, {'value': '0.22', 'spread': '2.87', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.20', 'spread': '2.84', 'groupId': 'OG000'}, {'value': '0.14', 'spread': '2.47', 'groupId': 'OG001'}, {'value': '-0.29', 'spread': '1.90', 'groupId': 'OG002'}, {'value': '0.39', 'spread': '1.79', 'groupId': 'OG003'}, {'value': '-0.02', 'spread': '1.92', 'groupId': 'OG004'}, {'value': '0.25', 'spread': '1.85', 'groupId': 'OG005'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '2.11', 'groupId': 'OG000'}, {'value': '0.71', 'spread': '2.88', 'groupId': 'OG001'}, {'value': '-0.54', 'spread': '2.57', 'groupId': 'OG002'}, {'value': '0.16', 'spread': '2.57', 'groupId': 'OG003'}, {'value': '-0.02', 'spread': '2.29', 'groupId': 'OG004'}, {'value': '0.36', 'spread': '2.37', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.76', 'spread': '3.81', 'groupId': 'OG000'}, {'value': '0.87', 'spread': '3.23', 'groupId': 'OG001'}, {'value': '0.17', 'spread': '2.39', 'groupId': 'OG002'}, {'value': '0.78', 'spread': '2.55', 'groupId': 'OG003'}, {'value': '0.47', 'spread': '2.88', 'groupId': 'OG004'}, {'value': '0.51', 'spread': '3.89', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '2.58', 'spread': '5.10', 'groupId': 'OG000'}, {'value': '7.80', 'spread': '14.07', 'groupId': 'OG001'}, {'value': '0.90', 'spread': '2.38', 'groupId': 'OG002'}, {'value': '0.85', 'spread': '0.35', 'groupId': 'OG003'}, {'value': '2.80', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '4.87', 'spread': '8.46', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Erythrocytes mean corpuscular volume was measured in femtolitres (fL).', 'unitOfMeasure': 'femtolitres (fL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.081', 'spread': '0.282', 'groupId': 'OG000'}, {'value': '0.004', 'spread': '0.213', 'groupId': 'OG001'}, {'value': '0.047', 'spread': '0.238', 'groupId': 'OG002'}, {'value': '-0.095', 'spread': '0.184', 'groupId': 'OG003'}, {'value': '-0.029', 'spread': '0.259', 'groupId': 'OG004'}, {'value': '-0.026', 'spread': '0.178', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.088', 'spread': '0.220', 'groupId': 'OG000'}, {'value': '0.010', 'spread': '0.193', 'groupId': 'OG001'}, {'value': '0.014', 'spread': '0.215', 'groupId': 'OG002'}, {'value': '-0.060', 'spread': '0.282', 'groupId': 'OG003'}, {'value': '-0.041', 'spread': '0.231', 'groupId': 'OG004'}, {'value': '-0.001', 'spread': '0.232', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.085', 'spread': '0.274', 'groupId': 'OG000'}, {'value': '0.019', 'spread': '0.217', 'groupId': 'OG001'}, {'value': '-0.018', 'spread': '0.193', 'groupId': 'OG002'}, {'value': '-0.066', 'spread': '0.215', 'groupId': 'OG003'}, {'value': '-0.053', 'spread': '0.281', 'groupId': 'OG004'}, {'value': '-0.015', 'spread': '0.216', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.053', 'spread': '0.277', 'groupId': 'OG000'}, {'value': '0.038', 'spread': '0.218', 'groupId': 'OG001'}, {'value': '0.011', 'spread': '0.243', 'groupId': 'OG002'}, {'value': '-0.019', 'spread': '0.145', 'groupId': 'OG003'}, {'value': '-0.060', 'spread': '0.278', 'groupId': 'OG004'}, {'value': '0.035', 'spread': '0.224', 'groupId': 'OG005'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.062', 'spread': '0.320', 'groupId': 'OG000'}, {'value': '0.022', 'spread': '0.245', 'groupId': 'OG001'}, {'value': '0.048', 'spread': '0.219', 'groupId': 'OG002'}, {'value': '0.009', 'spread': '0.224', 'groupId': 'OG003'}, {'value': '-0.028', 'spread': '0.240', 'groupId': 'OG004'}, {'value': '0.056', 'spread': '0.238', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.007', 'spread': '0.314', 'groupId': 'OG000'}, {'value': '0.092', 'spread': '0.258', 'groupId': 'OG001'}, {'value': '0.011', 'spread': '0.271', 'groupId': 'OG002'}, {'value': '-0.005', 'spread': '0.297', 'groupId': 'OG003'}, {'value': '-0.036', 'spread': '0.297', 'groupId': 'OG004'}, {'value': '0.039', 'spread': '0.228', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.090', 'spread': '0.346', 'groupId': 'OG000'}, {'value': '-0.135', 'spread': '0.184', 'groupId': 'OG001'}, {'value': '-0.195', 'spread': '0.165', 'groupId': 'OG002'}, {'value': '-0.215', 'spread': '0.035', 'groupId': 'OG003'}, {'value': '0.080', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-0.123', 'spread': '0.491', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Erythrocytes was measured in number of red blood cells per liter (10\\^12/L).', 'unitOfMeasure': '10^12 red blood cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.88', 'spread': '2.49', 'groupId': 'OG000'}, {'value': '0.27', 'spread': '2.07', 'groupId': 'OG001'}, {'value': '0.33', 'spread': '2.31', 'groupId': 'OG002'}, {'value': '-0.58', 'spread': '2.14', 'groupId': 'OG003'}, {'value': '-0.36', 'spread': '2.31', 'groupId': 'OG004'}, {'value': '-0.23', 'spread': '1.62', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.86', 'spread': '2.02', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '1.65', 'groupId': 'OG001'}, {'value': '-0.04', 'spread': '2.15', 'groupId': 'OG002'}, {'value': '-0.42', 'spread': '2.61', 'groupId': 'OG003'}, {'value': '-0.65', 'spread': '2.09', 'groupId': 'OG004'}, {'value': '-0.02', 'spread': '2.03', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.81', 'spread': '2.40', 'groupId': 'OG000'}, {'value': '0.24', 'spread': '2.07', 'groupId': 'OG001'}, {'value': '-0.26', 'spread': '1.86', 'groupId': 'OG002'}, {'value': '-0.26', 'spread': '1.80', 'groupId': 'OG003'}, {'value': '-0.48', 'spread': '2.57', 'groupId': 'OG004'}, {'value': '-0.03', 'spread': '2.02', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.33', 'spread': '2.46', 'groupId': 'OG000'}, {'value': '0.41', 'spread': '1.88', 'groupId': 'OG001'}, {'value': '-0.04', 'spread': '2.18', 'groupId': 'OG002'}, {'value': '0.02', 'spread': '1.73', 'groupId': 'OG003'}, {'value': '-0.51', 'spread': '2.59', 'groupId': 'OG004'}, {'value': '0.44', 'spread': '1.90', 'groupId': 'OG005'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.52', 'spread': '2.37', 'groupId': 'OG000'}, {'value': '0.55', 'spread': '2.51', 'groupId': 'OG001'}, {'value': '0.18', 'spread': '1.84', 'groupId': 'OG002'}, {'value': '0.14', 'spread': '2.61', 'groupId': 'OG003'}, {'value': '-0.22', 'spread': '2.46', 'groupId': 'OG004'}, {'value': '0.67', 'spread': '2.03', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.32', 'spread': '2.87', 'groupId': 'OG000'}, {'value': '1.25', 'spread': '2.29', 'groupId': 'OG001'}, {'value': '0.18', 'spread': '2.57', 'groupId': 'OG002'}, {'value': '0.30', 'spread': '2.99', 'groupId': 'OG003'}, {'value': '-0.05', 'spread': '2.75', 'groupId': 'OG004'}, {'value': '0.59', 'spread': '2.02', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.20', 'spread': '1.44', 'groupId': 'OG000'}, {'value': '1.98', 'spread': '6.92', 'groupId': 'OG001'}, {'value': '-1.20', 'spread': '1.90', 'groupId': 'OG002'}, {'value': '-1.50', 'spread': '0.14', 'groupId': 'OG003'}, {'value': '2.10', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '1.00', 'spread': '0.85', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Hematocrit was measured in volume percentage (%) of red blood cells in blood.', 'unitOfMeasure': 'volume % of red blood cells', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Basophils Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.03', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.03', 'groupId': 'OG002'}, {'value': '0.01', 'spread': '0.03', 'groupId': 'OG003'}, {'value': '0.00', 'spread': '0.04', 'groupId': 'OG004'}, {'value': '0.01', 'spread': '0.03', 'groupId': 'OG005'}]}]}, {'title': 'Basophils Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.02', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.04', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.04', 'groupId': 'OG002'}, {'value': '0.01', 'spread': '0.04', 'groupId': 'OG003'}, {'value': '0.01', 'spread': '0.04', 'groupId': 'OG004'}, {'value': '0.00', 'spread': '0.03', 'groupId': 'OG005'}]}]}, {'title': 'Basophils Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.03', 'groupId': 'OG002'}, {'value': '0.01', 'spread': '0.02', 'groupId': 'OG003'}, {'value': '0.01', 'spread': '0.05', 'groupId': 'OG004'}, {'value': '0.00', 'spread': '0.04', 'groupId': 'OG005'}]}]}, {'title': 'Basophils Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.04', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.04', 'groupId': 'OG002'}, {'value': '0.01', 'spread': '0.02', 'groupId': 'OG003'}, {'value': '0.00', 'spread': '0.04', 'groupId': 'OG004'}, {'value': '0.00', 'spread': '0.04', 'groupId': 'OG005'}]}]}, {'title': 'Basophils Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.04', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.04', 'groupId': 'OG001'}, {'value': '0.02', 'spread': '0.01', 'groupId': 'OG002'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG003'}, {'value': '0.02', 'spread': '0.04', 'groupId': 'OG004'}, {'value': '0.00', 'spread': '0.05', 'groupId': 'OG005'}]}]}, {'title': 'Basophils Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.04', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.03', 'groupId': 'OG002'}, {'value': '0.00', 'spread': '0.02', 'groupId': 'OG003'}, {'value': '0.01', 'spread': '0.04', 'groupId': 'OG004'}, {'value': '0.00', 'spread': '0.04', 'groupId': 'OG005'}]}]}, {'title': 'Basophils SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.05', 'groupId': 'OG000'}, {'value': '-0.03', 'spread': '0.05', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG002'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG003'}, {'value': '0.00', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.03', 'spread': '0.06', 'groupId': 'OG005'}]}]}, {'title': 'Eosinophils Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '0.02', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.07', 'groupId': 'OG002'}, {'value': '0.04', 'spread': '0.10', 'groupId': 'OG003'}, {'value': '0.02', 'spread': '0.11', 'groupId': 'OG004'}, {'value': '-0.02', 'spread': '0.12', 'groupId': 'OG005'}]}]}, {'title': 'Eosinophils Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.08', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.26', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.08', 'groupId': 'OG002'}, {'value': '0.05', 'spread': '0.11', 'groupId': 'OG003'}, {'value': '0.00', 'spread': '0.11', 'groupId': 'OG004'}, {'value': '0.01', 'spread': '0.11', 'groupId': 'OG005'}]}]}, {'title': 'Eosinophils Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.26', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.08', 'groupId': 'OG002'}, {'value': '0.02', 'spread': '0.11', 'groupId': 'OG003'}, {'value': '0.03', 'spread': '0.09', 'groupId': 'OG004'}, {'value': '0.00', 'spread': '0.18', 'groupId': 'OG005'}]}]}, {'title': 'Eosinophils Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.04', 'spread': '0.10', 'groupId': 'OG000'}, {'value': '0.02', 'spread': '0.19', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.08', 'groupId': 'OG002'}, {'value': '0.01', 'spread': '0.09', 'groupId': 'OG003'}, {'value': '0.05', 'spread': '0.16', 'groupId': 'OG004'}, {'value': '-0.01', 'spread': '0.17', 'groupId': 'OG005'}]}]}, {'title': 'Eosinophils Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.18', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.08', 'groupId': 'OG002'}, {'value': '0.04', 'spread': '0.17', 'groupId': 'OG003'}, {'value': '0.05', 'spread': '0.18', 'groupId': 'OG004'}, {'value': '-0.03', 'spread': '0.16', 'groupId': 'OG005'}]}]}, {'title': 'Eosinophils Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.09', 'groupId': 'OG000'}, {'value': '0.03', 'spread': '0.22', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.09', 'groupId': 'OG002'}, {'value': '0.00', 'spread': '0.08', 'groupId': 'OG003'}, {'value': '0.03', 'spread': '0.13', 'groupId': 'OG004'}, {'value': '-0.03', 'spread': '0.11', 'groupId': 'OG005'}]}]}, {'title': 'Eosinophils SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.10', 'groupId': 'OG001'}, {'value': '0.10', 'spread': '0.00', 'groupId': 'OG002'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG003'}, {'value': '-0.10', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.07', 'spread': '0.06', 'groupId': 'OG005'}]}]}, {'title': 'Leukocytes Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.16', 'spread': '1.30', 'groupId': 'OG000'}, {'value': '-0.59', 'spread': '1.34', 'groupId': 'OG001'}, {'value': '-0.15', 'spread': '1.43', 'groupId': 'OG002'}, {'value': '-0.63', 'spread': '1.82', 'groupId': 'OG003'}, {'value': '-0.19', 'spread': '1.51', 'groupId': 'OG004'}, {'value': '-0.48', 'spread': '0.90', 'groupId': 'OG005'}]}]}, {'title': 'Leukocytes Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.18', 'spread': '1.36', 'groupId': 'OG000'}, {'value': '-0.56', 'spread': '1.31', 'groupId': 'OG001'}, {'value': '-0.22', 'spread': '1.43', 'groupId': 'OG002'}, {'value': '-0.42', 'spread': '1.34', 'groupId': 'OG003'}, {'value': '-0.31', 'spread': '1.80', 'groupId': 'OG004'}, {'value': '-0.46', 'spread': '1.29', 'groupId': 'OG005'}]}]}, {'title': 'Leukocytes Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.17', 'spread': '1.51', 'groupId': 'OG000'}, {'value': '-0.36', 'spread': '1.31', 'groupId': 'OG001'}, {'value': '-0.23', 'spread': '1.38', 'groupId': 'OG002'}, {'value': '-0.54', 'spread': '1.14', 'groupId': 'OG003'}, {'value': '-0.36', 'spread': '1.73', 'groupId': 'OG004'}, {'value': '-0.34', 'spread': '1.24', 'groupId': 'OG005'}]}]}, {'title': 'Leukocytes Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.22', 'spread': '1.25', 'groupId': 'OG000'}, {'value': '-0.50', 'spread': '1.95', 'groupId': 'OG001'}, {'value': '-0.47', 'spread': '1.49', 'groupId': 'OG002'}, {'value': '-0.57', 'spread': '1.34', 'groupId': 'OG003'}, {'value': '-0.45', 'spread': '2.02', 'groupId': 'OG004'}, {'value': '-0.45', 'spread': '1.12', 'groupId': 'OG005'}]}]}, {'title': 'Leukocytes Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.10', 'spread': '1.34', 'groupId': 'OG000'}, {'value': '-0.67', 'spread': '1.55', 'groupId': 'OG001'}, {'value': '-0.24', 'spread': '1.94', 'groupId': 'OG002'}, {'value': '-0.37', 'spread': '1.55', 'groupId': 'OG003'}, {'value': '-0.30', 'spread': '1.76', 'groupId': 'OG004'}, {'value': '-0.45', 'spread': '0.87', 'groupId': 'OG005'}]}]}, {'title': 'Leukocytes Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '1.37', 'groupId': 'OG000'}, {'value': '-0.28', 'spread': '1.68', 'groupId': 'OG001'}, {'value': '-0.47', 'spread': '1.67', 'groupId': 'OG002'}, {'value': '-0.51', 'spread': '1.41', 'groupId': 'OG003'}, {'value': '-0.50', 'spread': '1.44', 'groupId': 'OG004'}, {'value': '-0.48', 'spread': '1.09', 'groupId': 'OG005'}]}]}, {'title': 'Leukocytes SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.98', 'groupId': 'OG000'}, {'value': '1.15', 'spread': '2.54', 'groupId': 'OG001'}, {'value': '0.95', 'spread': '1.43', 'groupId': 'OG002'}, {'value': '-0.65', 'spread': '0.78', 'groupId': 'OG003'}, {'value': '0.20', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.30', 'spread': '0.40', 'groupId': 'OG005'}]}]}, {'title': 'Lymphocytes Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.12', 'spread': '0.36', 'groupId': 'OG000'}, {'value': '-0.05', 'spread': '0.30', 'groupId': 'OG001'}, {'value': '0.15', 'spread': '0.42', 'groupId': 'OG002'}, {'value': '0.13', 'spread': '0.34', 'groupId': 'OG003'}, {'value': '0.14', 'spread': '0.46', 'groupId': 'OG004'}, {'value': '0.00', 'spread': '0.45', 'groupId': 'OG005'}]}]}, {'title': 'Lymphocytes Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.32', 'groupId': 'OG000'}, {'value': '-0.11', 'spread': '0.30', 'groupId': 'OG001'}, {'value': '0.09', 'spread': '0.34', 'groupId': 'OG002'}, {'value': '0.09', 'spread': '0.40', 'groupId': 'OG003'}, {'value': '0.12', 'spread': '0.34', 'groupId': 'OG004'}, {'value': '-0.08', 'spread': '0.37', 'groupId': 'OG005'}]}]}, {'title': 'Lymphocytes Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.40', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.33', 'groupId': 'OG001'}, {'value': '0.15', 'spread': '0.43', 'groupId': 'OG002'}, {'value': '0.08', 'spread': '0.42', 'groupId': 'OG003'}, {'value': '0.11', 'spread': '0.36', 'groupId': 'OG004'}, {'value': '0.06', 'spread': '0.36', 'groupId': 'OG005'}]}]}, {'title': 'Lymphocytes Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.46', 'groupId': 'OG000'}, {'value': '-0.08', 'spread': '0.43', 'groupId': 'OG001'}, {'value': '0.03', 'spread': '0.31', 'groupId': 'OG002'}, {'value': '0.04', 'spread': '0.43', 'groupId': 'OG003'}, {'value': '0.05', 'spread': '0.37', 'groupId': 'OG004'}, {'value': '-0.05', 'spread': '0.40', 'groupId': 'OG005'}]}]}, {'title': 'Lymphocytes Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.37', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.31', 'groupId': 'OG001'}, {'value': '0.09', 'spread': '0.40', 'groupId': 'OG002'}, {'value': '0.11', 'spread': '0.33', 'groupId': 'OG003'}, {'value': '0.15', 'spread': '0.45', 'groupId': 'OG004'}, {'value': '0.06', 'spread': '0.42', 'groupId': 'OG005'}]}]}, {'title': 'Lymphocytes Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.38', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '0.35', 'groupId': 'OG001'}, {'value': '0.06', 'spread': '0.38', 'groupId': 'OG002'}, {'value': '0.07', 'spread': '0.48', 'groupId': 'OG003'}, {'value': '0.14', 'spread': '0.38', 'groupId': 'OG004'}, {'value': '-0.04', 'spread': '0.37', 'groupId': 'OG005'}]}]}, {'title': 'Lymphocytes SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.25', 'spread': '0.24', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '0.40', 'groupId': 'OG001'}, {'value': '0.23', 'spread': '0.19', 'groupId': 'OG002'}, {'value': '0.25', 'spread': '0.21', 'groupId': 'OG003'}, {'value': '0.00', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.50', 'spread': '0.44', 'groupId': 'OG005'}]}]}, {'title': 'Monocytes Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.02', 'spread': '0.16', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.12', 'groupId': 'OG001'}, {'value': '0.02', 'spread': '0.15', 'groupId': 'OG002'}, {'value': '0.02', 'spread': '0.11', 'groupId': 'OG003'}, {'value': '0.02', 'spread': '0.17', 'groupId': 'OG004'}, {'value': '-0.03', 'spread': '0.14', 'groupId': 'OG005'}]}]}, {'title': 'Monocytes Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.14', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.14', 'groupId': 'OG002'}, {'value': '0.04', 'spread': '0.15', 'groupId': 'OG003'}, {'value': '-0.04', 'spread': '0.17', 'groupId': 'OG004'}, {'value': '-0.03', 'spread': '0.15', 'groupId': 'OG005'}]}]}, {'title': 'Monocytes Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.16', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.15', 'groupId': 'OG002'}, {'value': '0.03', 'spread': '0.13', 'groupId': 'OG003'}, {'value': '-0.01', 'spread': '0.17', 'groupId': 'OG004'}, {'value': '0.02', 'spread': '0.17', 'groupId': 'OG005'}]}]}, {'title': 'Monocytes Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.18', 'groupId': 'OG001'}, {'value': '0.02', 'spread': '0.15', 'groupId': 'OG002'}, {'value': '0.00', 'spread': '0.11', 'groupId': 'OG003'}, {'value': '-0.02', 'spread': '0.22', 'groupId': 'OG004'}, {'value': '-0.03', 'spread': '0.18', 'groupId': 'OG005'}]}]}, {'title': 'Monocytes Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-0.03', 'spread': '0.11', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.16', 'groupId': 'OG002'}, {'value': '-0.01', 'spread': '0.14', 'groupId': 'OG003'}, {'value': '-0.04', 'spread': '0.17', 'groupId': 'OG004'}, {'value': '-0.02', 'spread': '0.15', 'groupId': 'OG005'}]}]}, {'title': 'Monocytes Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.16', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-0.02', 'spread': '0.15', 'groupId': 'OG002'}, {'value': '-0.01', 'spread': '0.18', 'groupId': 'OG003'}, {'value': '-0.07', 'spread': '0.17', 'groupId': 'OG004'}, {'value': '-0.01', 'spread': '0.14', 'groupId': 'OG005'}]}]}, {'title': 'Monocytes SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.10', 'spread': '0.22', 'groupId': 'OG000'}, {'value': '0.10', 'spread': '0.22', 'groupId': 'OG001'}, {'value': '0.03', 'spread': '0.10', 'groupId': 'OG002'}, {'value': '0.00', 'spread': '0.00', 'groupId': 'OG003'}, {'value': '-0.30', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-0.07', 'spread': '0.21', 'groupId': 'OG005'}]}]}, {'title': 'Neutrophils Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.02', 'spread': '1.16', 'groupId': 'OG000'}, {'value': '-0.55', 'spread': '1.12', 'groupId': 'OG001'}, {'value': '-0.32', 'spread': '1.25', 'groupId': 'OG002'}, {'value': '-0.81', 'spread': '1.81', 'groupId': 'OG003'}, {'value': '-0.37', 'spread': '1.20', 'groupId': 'OG004'}, {'value': '-0.44', 'spread': '0.76', 'groupId': 'OG005'}]}]}, {'title': 'Neutrophils Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.09', 'spread': '1.29', 'groupId': 'OG000'}, {'value': '-0.43', 'spread': '1.05', 'groupId': 'OG001'}, {'value': '-0.31', 'spread': '1.33', 'groupId': 'OG002'}, {'value': '-0.59', 'spread': '1.09', 'groupId': 'OG003'}, {'value': '-0.41', 'spread': '1.64', 'groupId': 'OG004'}, {'value': '-0.36', 'spread': '1.13', 'groupId': 'OG005'}]}]}, {'title': 'Neutrophils Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.04', 'spread': '1.30', 'groupId': 'OG000'}, {'value': '-0.35', 'spread': '1.07', 'groupId': 'OG001'}, {'value': '-0.39', 'spread': '1.31', 'groupId': 'OG002'}, {'value': '-0.68', 'spread': '1.02', 'groupId': 'OG003'}, {'value': '-0.48', 'spread': '1.60', 'groupId': 'OG004'}, {'value': '-0.40', 'spread': '1.18', 'groupId': 'OG005'}]}]}, {'title': 'Neutrophils Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.36', 'spread': '0.98', 'groupId': 'OG000'}, {'value': '-0.43', 'spread': '1.64', 'groupId': 'OG001'}, {'value': '-0.49', 'spread': '1.38', 'groupId': 'OG002'}, {'value': '-0.54', 'spread': '1.16', 'groupId': 'OG003'}, {'value': '-0.50', 'spread': '1.78', 'groupId': 'OG004'}, {'value': '-0.36', 'spread': '1.01', 'groupId': 'OG005'}]}]}, {'title': 'Neutrophils Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '1.18', 'groupId': 'OG000'}, {'value': '-0.61', 'spread': '1.40', 'groupId': 'OG001'}, {'value': '-0.34', 'spread': '1.72', 'groupId': 'OG002'}, {'value': '-0.57', 'spread': '1.28', 'groupId': 'OG003'}, {'value': '-0.45', 'spread': '1.61', 'groupId': 'OG004'}, {'value': '-0.47', 'spread': '0.80', 'groupId': 'OG005'}]}]}, {'title': 'Neutrophils Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '38', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.11', 'spread': '1.17', 'groupId': 'OG000'}, {'value': '-0.33', 'spread': '1.50', 'groupId': 'OG001'}, {'value': '-0.49', 'spread': '1.50', 'groupId': 'OG002'}, {'value': '-0.57', 'spread': '1.20', 'groupId': 'OG003'}, {'value': '-0.59', 'spread': '1.28', 'groupId': 'OG004'}, {'value': '-0.39', 'spread': '0.93', 'groupId': 'OG005'}]}]}, {'title': 'Neutrophils SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.45', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '1.88', 'groupId': 'OG001'}, {'value': '0.65', 'spread': '1.20', 'groupId': 'OG002'}, {'value': '-0.95', 'spread': '0.49', 'groupId': 'OG003'}, {'value': '0.50', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-0.13', 'spread': '0.38', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Basophils, eosinophils, leukocytes, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10\\^9/L).', 'unitOfMeasure': '10^9 white blood cells per liter', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Calcium, Chloride, Potassium, Magnesium, Sodium, Urea Nitrogen, Cholesterol, Glucose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Calcium Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.010', 'spread': '0.076', 'groupId': 'OG000'}, {'value': '0.011', 'spread': '0.088', 'groupId': 'OG001'}, {'value': '-0.021', 'spread': '0.126', 'groupId': 'OG002'}, {'value': '-0.017', 'spread': '0.076', 'groupId': 'OG003'}, {'value': '0.000', 'spread': '0.077', 'groupId': 'OG004'}, {'value': '-0.010', 'spread': '0.080', 'groupId': 'OG005'}]}]}, {'title': 'Calcium Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.003', 'spread': '0.082', 'groupId': 'OG000'}, {'value': '0.034', 'spread': '0.094', 'groupId': 'OG001'}, {'value': '-0.007', 'spread': '0.092', 'groupId': 'OG002'}, {'value': '0.004', 'spread': '0.074', 'groupId': 'OG003'}, {'value': '0.006', 'spread': '0.088', 'groupId': 'OG004'}, {'value': '-0.006', 'spread': '0.085', 'groupId': 'OG005'}]}]}, {'title': 'Calcium Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.029', 'spread': '0.073', 'groupId': 'OG000'}, {'value': '0.012', 'spread': '0.099', 'groupId': 'OG001'}, {'value': '-0.020', 'spread': '0.106', 'groupId': 'OG002'}, {'value': '-0.008', 'spread': '0.074', 'groupId': 'OG003'}, {'value': '0.005', 'spread': '0.099', 'groupId': 'OG004'}, {'value': '-0.010', 'spread': '0.084', 'groupId': 'OG005'}]}]}, {'title': 'Calcium Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.033', 'spread': '0.070', 'groupId': 'OG000'}, {'value': '0.009', 'spread': '0.079', 'groupId': 'OG001'}, {'value': '-0.019', 'spread': '0.091', 'groupId': 'OG002'}, {'value': '-0.008', 'spread': '0.092', 'groupId': 'OG003'}, {'value': '-0.026', 'spread': '0.086', 'groupId': 'OG004'}, {'value': '-0.027', 'spread': '0.100', 'groupId': 'OG005'}]}]}, {'title': 'Calcium Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.023', 'spread': '0.084', 'groupId': 'OG000'}, {'value': '0.001', 'spread': '0.106', 'groupId': 'OG001'}, {'value': '-0.027', 'spread': '0.099', 'groupId': 'OG002'}, {'value': '0.019', 'spread': '0.089', 'groupId': 'OG003'}, {'value': '-0.002', 'spread': '0.089', 'groupId': 'OG004'}, {'value': '-0.016', 'spread': '0.084', 'groupId': 'OG005'}]}]}, {'title': 'Calcium Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.011', 'spread': '0.095', 'groupId': 'OG000'}, {'value': '0.025', 'spread': '0.092', 'groupId': 'OG001'}, {'value': '-0.038', 'spread': '0.120', 'groupId': 'OG002'}, {'value': '0.001', 'spread': '0.093', 'groupId': 'OG003'}, {'value': '-0.019', 'spread': '0.121', 'groupId': 'OG004'}, {'value': '-0.001', 'spread': '0.092', 'groupId': 'OG005'}]}]}, {'title': 'Calcium SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.095', 'spread': '0.083', 'groupId': 'OG000'}, {'value': '-0.050', 'spread': '0.109', 'groupId': 'OG001'}, {'value': '-0.073', 'spread': '0.045', 'groupId': 'OG002'}, {'value': '-0.125', 'spread': '0.134', 'groupId': 'OG003'}, {'value': '0.020', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.020', 'spread': '0.193', 'groupId': 'OG005'}]}]}, {'title': 'Chloride Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '1.8', 'groupId': 'OG000'}, {'value': '0.6', 'spread': '2.0', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '2.3', 'groupId': 'OG002'}, {'value': '0.6', 'spread': '2.5', 'groupId': 'OG003'}, {'value': '0.3', 'spread': '2.1', 'groupId': 'OG004'}, {'value': '0.1', 'spread': '1.8', 'groupId': 'OG005'}]}]}, {'title': 'Chloride Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '2.3', 'groupId': 'OG000'}, {'value': '0.1', 'spread': '2.4', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '2.2', 'groupId': 'OG002'}, {'value': '0.4', 'spread': '2.3', 'groupId': 'OG003'}, {'value': '0.5', 'spread': '2.1', 'groupId': 'OG004'}, {'value': '0.1', 'spread': '1.9', 'groupId': 'OG005'}]}]}, {'title': 'Chloride Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.1', 'spread': '1.8', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '2.1', 'groupId': 'OG001'}, {'value': '0.0', 'spread': '2.5', 'groupId': 'OG002'}, {'value': '0.2', 'spread': '2.3', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '2.6', 'groupId': 'OG004'}, {'value': '-0.1', 'spread': '1.9', 'groupId': 'OG005'}]}]}, {'title': 'Chloride Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '2.1', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '2.3', 'groupId': 'OG001'}, {'value': '-0.6', 'spread': '1.7', 'groupId': 'OG002'}, {'value': '0.0', 'spread': '2.4', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '3.0', 'groupId': 'OG004'}, {'value': '0.1', 'spread': '2.0', 'groupId': 'OG005'}]}]}, {'title': 'Chloride Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '2.1', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '2.3', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '2.0', 'groupId': 'OG002'}, {'value': '-0.1', 'spread': '2.9', 'groupId': 'OG003'}, {'value': '0.1', 'spread': '2.4', 'groupId': 'OG004'}, {'value': '0.1', 'spread': '2.3', 'groupId': 'OG005'}]}]}, {'title': 'Chloride Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '2.5', 'groupId': 'OG001'}, {'value': '-0.2', 'spread': '2.0', 'groupId': 'OG002'}, {'value': '0.2', 'spread': '2.3', 'groupId': 'OG003'}, {'value': '0.8', 'spread': '2.4', 'groupId': 'OG004'}, {'value': '0.1', 'spread': '2.2', 'groupId': 'OG005'}]}]}, {'title': 'Chloride SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '1.6', 'groupId': 'OG000'}, {'value': '3.0', 'spread': '2.7', 'groupId': 'OG001'}, {'value': '0.5', 'spread': '5.4', 'groupId': 'OG002'}, {'value': '2.0', 'spread': '0.0', 'groupId': 'OG003'}, {'value': '0.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.3', 'spread': '2.1', 'groupId': 'OG005'}]}]}, {'title': 'Potassium Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.45', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.33', 'groupId': 'OG001'}, {'value': '0.05', 'spread': '0.41', 'groupId': 'OG002'}, {'value': '0.02', 'spread': '0.36', 'groupId': 'OG003'}, {'value': '-0.03', 'spread': '0.32', 'groupId': 'OG004'}, {'value': '0.04', 'spread': '0.29', 'groupId': 'OG005'}]}]}, {'title': 'Potassium Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.30', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.33', 'groupId': 'OG001'}, {'value': '0.02', 'spread': '0.32', 'groupId': 'OG002'}, {'value': '-0.06', 'spread': '0.29', 'groupId': 'OG003'}, {'value': '0.05', 'spread': '0.37', 'groupId': 'OG004'}, {'value': '-0.03', 'spread': '0.39', 'groupId': 'OG005'}]}]}, {'title': 'Potassium Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.09', 'spread': '0.40', 'groupId': 'OG000'}, {'value': '0.12', 'spread': '0.41', 'groupId': 'OG001'}, {'value': '0.09', 'spread': '0.38', 'groupId': 'OG002'}, {'value': '0.01', 'spread': '0.34', 'groupId': 'OG003'}, {'value': '0.05', 'spread': '0.40', 'groupId': 'OG004'}, {'value': '0.03', 'spread': '0.33', 'groupId': 'OG005'}]}]}, {'title': 'Potassium Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.32', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '0.35', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.31', 'groupId': 'OG002'}, {'value': '-0.07', 'spread': '0.33', 'groupId': 'OG003'}, {'value': '-0.07', 'spread': '0.34', 'groupId': 'OG004'}, {'value': '-0.02', 'spread': '0.35', 'groupId': 'OG005'}]}]}, {'title': 'Potassium Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.39', 'groupId': 'OG000'}, {'value': '0.07', 'spread': '0.36', 'groupId': 'OG001'}, {'value': '0.12', 'spread': '0.38', 'groupId': 'OG002'}, {'value': '-0.06', 'spread': '0.38', 'groupId': 'OG003'}, {'value': '-0.12', 'spread': '0.40', 'groupId': 'OG004'}, {'value': '0.02', 'spread': '0.35', 'groupId': 'OG005'}]}]}, {'title': 'Potassium Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.35', 'groupId': 'OG000'}, {'value': '0.08', 'spread': '0.34', 'groupId': 'OG001'}, {'value': '0.08', 'spread': '0.37', 'groupId': 'OG002'}, {'value': '-0.06', 'spread': '0.37', 'groupId': 'OG003'}, {'value': '-0.07', 'spread': '0.37', 'groupId': 'OG004'}, {'value': '-0.06', 'spread': '0.33', 'groupId': 'OG005'}]}]}, {'title': 'Potassium SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.10', 'spread': '0.36', 'groupId': 'OG000'}, {'value': '0.10', 'spread': '0.37', 'groupId': 'OG001'}, {'value': '-0.10', 'spread': '0.29', 'groupId': 'OG002'}, {'value': '-0.45', 'spread': '0.07', 'groupId': 'OG003'}, {'value': '0.20', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-0.20', 'spread': '0.30', 'groupId': 'OG005'}]}]}, {'title': 'Magnesium Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.010', 'spread': '0.074', 'groupId': 'OG000'}, {'value': '-0.002', 'spread': '0.052', 'groupId': 'OG001'}, {'value': '-0.020', 'spread': '0.069', 'groupId': 'OG002'}, {'value': '0.005', 'spread': '0.079', 'groupId': 'OG003'}, {'value': '-0.007', 'spread': '0.077', 'groupId': 'OG004'}, {'value': '-0.009', 'spread': '0.064', 'groupId': 'OG005'}]}]}, {'title': 'Magnesium Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.012', 'spread': '0.063', 'groupId': 'OG000'}, {'value': '-0.004', 'spread': '0.064', 'groupId': 'OG001'}, {'value': '-0.010', 'spread': '0.065', 'groupId': 'OG002'}, {'value': '0.001', 'spread': '0.068', 'groupId': 'OG003'}, {'value': '-0.017', 'spread': '0.086', 'groupId': 'OG004'}, {'value': '0.005', 'spread': '0.075', 'groupId': 'OG005'}]}]}, {'title': 'Magnesium Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.023', 'spread': '0.077', 'groupId': 'OG000'}, {'value': '-0.004', 'spread': '0.062', 'groupId': 'OG001'}, {'value': '-0.017', 'spread': '0.046', 'groupId': 'OG002'}, {'value': '0.008', 'spread': '0.071', 'groupId': 'OG003'}, {'value': '-0.017', 'spread': '0.067', 'groupId': 'OG004'}, {'value': '-0.013', 'spread': '0.070', 'groupId': 'OG005'}]}]}, {'title': 'Magnesium Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.013', 'spread': '0.054', 'groupId': 'OG000'}, {'value': '-0.014', 'spread': '0.053', 'groupId': 'OG001'}, {'value': '-0.013', 'spread': '0.057', 'groupId': 'OG002'}, {'value': '-0.008', 'spread': '0.065', 'groupId': 'OG003'}, {'value': '-0.020', 'spread': '0.073', 'groupId': 'OG004'}, {'value': '-0.017', 'spread': '0.063', 'groupId': 'OG005'}]}]}, {'title': 'Magnesium Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.026', 'spread': '0.070', 'groupId': 'OG000'}, {'value': '-0.023', 'spread': '0.042', 'groupId': 'OG001'}, {'value': '-0.023', 'spread': '0.063', 'groupId': 'OG002'}, {'value': '0.003', 'spread': '0.071', 'groupId': 'OG003'}, {'value': '-0.019', 'spread': '0.072', 'groupId': 'OG004'}, {'value': '-0.021', 'spread': '0.058', 'groupId': 'OG005'}]}]}, {'title': 'Magnesium Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.014', 'spread': '0.093', 'groupId': 'OG000'}, {'value': '0.007', 'spread': '0.074', 'groupId': 'OG001'}, {'value': '-0.025', 'spread': '0.069', 'groupId': 'OG002'}, {'value': '0.009', 'spread': '0.074', 'groupId': 'OG003'}, {'value': '-0.017', 'spread': '0.075', 'groupId': 'OG004'}, {'value': '-0.008', 'spread': '0.056', 'groupId': 'OG005'}]}]}, {'title': 'Magnesium SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.053', 'spread': '0.093', 'groupId': 'OG000'}, {'value': '0.110', 'spread': '0.295', 'groupId': 'OG001'}, {'value': '-0.035', 'spread': '0.047', 'groupId': 'OG002'}, {'value': '-0.050', 'spread': '0.057', 'groupId': 'OG003'}, {'value': '-0.060', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-0.023', 'spread': '0.025', 'groupId': 'OG005'}]}]}, {'title': 'Sodium Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.1', 'spread': '1.8', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '1.7', 'groupId': 'OG001'}, {'value': '0.3', 'spread': '2.7', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '1.9', 'groupId': 'OG003'}, {'value': '0.0', 'spread': '2.2', 'groupId': 'OG004'}, {'value': '0.0', 'spread': '1.4', 'groupId': 'OG005'}]}]}, {'title': 'Sodium Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '1.4', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '1.8', 'groupId': 'OG002'}, {'value': '0.0', 'spread': '2.0', 'groupId': 'OG003'}, {'value': '0.2', 'spread': '2.3', 'groupId': 'OG004'}, {'value': '0.0', 'spread': '1.5', 'groupId': 'OG005'}]}]}, {'title': 'Sodium Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '1.7', 'groupId': 'OG001'}, {'value': '0.2', 'spread': '1.7', 'groupId': 'OG002'}, {'value': '-0.2', 'spread': '1.7', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '2.3', 'groupId': 'OG004'}, {'value': '-0.2', 'spread': '1.7', 'groupId': 'OG005'}]}]}, {'title': 'Sodium Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '2.0', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '2.1', 'groupId': 'OG001'}, {'value': '-0.8', 'spread': '1.6', 'groupId': 'OG002'}, {'value': '-0.1', 'spread': '1.9', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '2.9', 'groupId': 'OG004'}, {'value': '-0.3', 'spread': '1.7', 'groupId': 'OG005'}]}]}, {'title': 'Sodium Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.6', 'spread': '2.0', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '2.8', 'groupId': 'OG001'}, {'value': '-0.2', 'spread': '1.8', 'groupId': 'OG002'}, {'value': '-0.2', 'spread': '2.0', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '2.2', 'groupId': 'OG004'}, {'value': '-0.6', 'spread': '2.0', 'groupId': 'OG005'}]}]}, {'title': 'Sodium Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '2.0', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '1.7', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '1.7', 'groupId': 'OG002'}, {'value': '-0.2', 'spread': '2.0', 'groupId': 'OG003'}, {'value': '-0.2', 'spread': '2.4', 'groupId': 'OG004'}, {'value': '-0.3', 'spread': '1.9', 'groupId': 'OG005'}]}]}, {'title': 'Sodium SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '2.1', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '1.7', 'groupId': 'OG001'}, {'value': '-2.0', 'spread': '2.2', 'groupId': 'OG002'}, {'value': '-2.0', 'spread': '2.8', 'groupId': 'OG003'}, {'value': '-1.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-1.7', 'spread': '1.2', 'groupId': 'OG005'}]}]}, {'title': 'Urea Nitrogen Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.16', 'spread': '1.09', 'groupId': 'OG000'}, {'value': '0.11', 'spread': '1.12', 'groupId': 'OG001'}, {'value': '0.27', 'spread': '1.19', 'groupId': 'OG002'}, {'value': '0.34', 'spread': '1.22', 'groupId': 'OG003'}, {'value': '0.27', 'spread': '1.24', 'groupId': 'OG004'}, {'value': '0.21', 'spread': '0.88', 'groupId': 'OG005'}]}]}, {'title': 'Urea Nitrogen Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '1.16', 'groupId': 'OG000'}, {'value': '-0.03', 'spread': '1.25', 'groupId': 'OG001'}, {'value': '0.24', 'spread': '1.16', 'groupId': 'OG002'}, {'value': '0.16', 'spread': '1.17', 'groupId': 'OG003'}, {'value': '0.27', 'spread': '1.17', 'groupId': 'OG004'}, {'value': '0.37', 'spread': '1.03', 'groupId': 'OG005'}]}]}, {'title': 'Urea Nitrogen Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.14', 'spread': '1.16', 'groupId': 'OG000'}, {'value': '0.48', 'spread': '1.52', 'groupId': 'OG001'}, {'value': '0.50', 'spread': '1.31', 'groupId': 'OG002'}, {'value': '-0.03', 'spread': '1.20', 'groupId': 'OG003'}, {'value': '-0.11', 'spread': '1.08', 'groupId': 'OG004'}, {'value': '0.15', 'spread': '1.04', 'groupId': 'OG005'}]}]}, {'title': 'Urea Nitrogen Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.12', 'spread': '0.96', 'groupId': 'OG000'}, {'value': '0.21', 'spread': '1.40', 'groupId': 'OG001'}, {'value': '0.41', 'spread': '1.14', 'groupId': 'OG002'}, {'value': '0.19', 'spread': '1.31', 'groupId': 'OG003'}, {'value': '0.29', 'spread': '1.14', 'groupId': 'OG004'}, {'value': '0.12', 'spread': '0.93', 'groupId': 'OG005'}]}]}, {'title': 'Urea Nitrogen Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.28', 'spread': '1.29', 'groupId': 'OG000'}, {'value': '0.14', 'spread': '1.33', 'groupId': 'OG001'}, {'value': '0.32', 'spread': '1.08', 'groupId': 'OG002'}, {'value': '-0.08', 'spread': '1.58', 'groupId': 'OG003'}, {'value': '0.33', 'spread': '1.30', 'groupId': 'OG004'}, {'value': '0.35', 'spread': '0.88', 'groupId': 'OG005'}]}]}, {'title': 'Urea Nitrogen Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.17', 'spread': '1.35', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '1.37', 'groupId': 'OG001'}, {'value': '0.39', 'spread': '1.14', 'groupId': 'OG002'}, {'value': '0.08', 'spread': '1.13', 'groupId': 'OG003'}, {'value': '0.13', 'spread': '1.08', 'groupId': 'OG004'}, {'value': '0.01', 'spread': '0.85', 'groupId': 'OG005'}]}]}, {'title': 'Urea Nitrogen SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.65', 'spread': '1.74', 'groupId': 'OG000'}, {'value': '0.80', 'spread': '1.19', 'groupId': 'OG001'}, {'value': '0.78', 'spread': '3.27', 'groupId': 'OG002'}, {'value': '-0.65', 'spread': '2.05', 'groupId': 'OG003'}, {'value': '-0.30', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.77', 'spread': '1.27', 'groupId': 'OG005'}]}]}, {'title': 'Cholesterol Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.04', 'spread': '0.47', 'groupId': 'OG000'}, {'value': '-0.06', 'spread': '0.54', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.65', 'groupId': 'OG002'}, {'value': '-0.09', 'spread': '0.59', 'groupId': 'OG003'}, {'value': '0.12', 'spread': '0.65', 'groupId': 'OG004'}, {'value': '0.06', 'spread': '0.34', 'groupId': 'OG005'}]}]}, {'title': 'Cholesterol Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.13', 'spread': '0.71', 'groupId': 'OG000'}, {'value': '0.03', 'spread': '0.63', 'groupId': 'OG001'}, {'value': '0.12', 'spread': '0.58', 'groupId': 'OG002'}, {'value': '-0.11', 'spread': '0.52', 'groupId': 'OG003'}, {'value': '0.12', 'spread': '1.04', 'groupId': 'OG004'}, {'value': '0.05', 'spread': '0.57', 'groupId': 'OG005'}]}]}, {'title': 'Cholesterol Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.06', 'spread': '0.59', 'groupId': 'OG000'}, {'value': '0.04', 'spread': '0.63', 'groupId': 'OG001'}, {'value': '0.17', 'spread': '0.55', 'groupId': 'OG002'}, {'value': '-0.31', 'spread': '0.88', 'groupId': 'OG003'}, {'value': '0.00', 'spread': '1.30', 'groupId': 'OG004'}, {'value': '0.05', 'spread': '0.66', 'groupId': 'OG005'}]}]}, {'title': 'Cholesterol Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.46', 'groupId': 'OG000'}, {'value': '-0.02', 'spread': '0.73', 'groupId': 'OG001'}, {'value': '0.17', 'spread': '0.56', 'groupId': 'OG002'}, {'value': '-0.24', 'spread': '0.70', 'groupId': 'OG003'}, {'value': '-0.24', 'spread': '1.32', 'groupId': 'OG004'}, {'value': '0.08', 'spread': '0.60', 'groupId': 'OG005'}]}]}, {'title': 'Cholesterol Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.08', 'spread': '0.67', 'groupId': 'OG000'}, {'value': '-0.17', 'spread': '0.68', 'groupId': 'OG001'}, {'value': '0.16', 'spread': '0.64', 'groupId': 'OG002'}, {'value': '-0.13', 'spread': '0.83', 'groupId': 'OG003'}, {'value': '-0.17', 'spread': '1.22', 'groupId': 'OG004'}, {'value': '0.01', 'spread': '0.48', 'groupId': 'OG005'}]}]}, {'title': 'Cholesterol Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.20', 'spread': '0.88', 'groupId': 'OG000'}, {'value': '-0.07', 'spread': '0.62', 'groupId': 'OG001'}, {'value': '0.11', 'spread': '0.62', 'groupId': 'OG002'}, {'value': '-0.18', 'spread': '0.77', 'groupId': 'OG003'}, {'value': '0.01', 'spread': '1.29', 'groupId': 'OG004'}, {'value': '-0.05', 'spread': '0.76', 'groupId': 'OG005'}]}]}, {'title': 'Cholesterol SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.28', 'spread': '0.30', 'groupId': 'OG000'}, {'value': '-0.83', 'spread': '1.56', 'groupId': 'OG001'}, {'value': '0.38', 'spread': '0.52', 'groupId': 'OG002'}, {'value': '-0.80', 'spread': '0.14', 'groupId': 'OG003'}, {'value': '0.20', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.40', 'spread': '0.44', 'groupId': 'OG005'}]}]}, {'title': 'Glucose Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.50', 'spread': '1.59', 'groupId': 'OG000'}, {'value': '0.12', 'spread': '0.82', 'groupId': 'OG001'}, {'value': '-0.14', 'spread': '1.00', 'groupId': 'OG002'}, {'value': '-0.06', 'spread': '1.14', 'groupId': 'OG003'}, {'value': '0.07', 'spread': '1.10', 'groupId': 'OG004'}, {'value': '0.22', 'spread': '0.70', 'groupId': 'OG005'}]}]}, {'title': 'Glucose Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.29', 'spread': '1.62', 'groupId': 'OG000'}, {'value': '0.17', 'spread': '1.23', 'groupId': 'OG001'}, {'value': '-0.05', 'spread': '0.92', 'groupId': 'OG002'}, {'value': '-0.20', 'spread': '1.13', 'groupId': 'OG003'}, {'value': '0.03', 'spread': '1.09', 'groupId': 'OG004'}, {'value': '0.05', 'spread': '0.67', 'groupId': 'OG005'}]}]}, {'title': 'Glucose Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.37', 'spread': '1.42', 'groupId': 'OG000'}, {'value': '0.25', 'spread': '1.22', 'groupId': 'OG001'}, {'value': '-0.12', 'spread': '1.03', 'groupId': 'OG002'}, {'value': '-0.09', 'spread': '1.24', 'groupId': 'OG003'}, {'value': '0.37', 'spread': '1.20', 'groupId': 'OG004'}, {'value': '0.19', 'spread': '0.92', 'groupId': 'OG005'}]}]}, {'title': 'Glucose Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.44', 'spread': '1.42', 'groupId': 'OG000'}, {'value': '0.30', 'spread': '1.15', 'groupId': 'OG001'}, {'value': '-0.04', 'spread': '1.26', 'groupId': 'OG002'}, {'value': '0.02', 'spread': '1.60', 'groupId': 'OG003'}, {'value': '0.21', 'spread': '1.30', 'groupId': 'OG004'}, {'value': '0.29', 'spread': '1.27', 'groupId': 'OG005'}]}]}, {'title': 'Glucose Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.37', 'spread': '1.48', 'groupId': 'OG000'}, {'value': '0.22', 'spread': '1.48', 'groupId': 'OG001'}, {'value': '-0.15', 'spread': '0.87', 'groupId': 'OG002'}, {'value': '-0.06', 'spread': '1.43', 'groupId': 'OG003'}, {'value': '0.11', 'spread': '1.10', 'groupId': 'OG004'}, {'value': '0.03', 'spread': '0.97', 'groupId': 'OG005'}]}]}, {'title': 'Glucose Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.22', 'spread': '1.27', 'groupId': 'OG000'}, {'value': '0.01', 'spread': '1.08', 'groupId': 'OG001'}, {'value': '0.02', 'spread': '1.35', 'groupId': 'OG002'}, {'value': '-0.17', 'spread': '1.23', 'groupId': 'OG003'}, {'value': '-0.15', 'spread': '0.88', 'groupId': 'OG004'}, {'value': '0.04', 'spread': '0.95', 'groupId': 'OG005'}]}]}, {'title': 'Glucose SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.40', 'spread': '0.48', 'groupId': 'OG000'}, {'value': '0.75', 'spread': '0.89', 'groupId': 'OG001'}, {'value': '-0.33', 'spread': '0.67', 'groupId': 'OG002'}, {'value': '-0.25', 'spread': '0.49', 'groupId': 'OG003'}, {'value': '0.20', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-0.17', 'spread': '0.61', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Calcium, chloride, potassium, magnesium, sodium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).', 'unitOfMeasure': 'mmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Lactate Dehydrogenase, Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Lactate Dehydrogenase Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'spread': '29.4', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '24.8', 'groupId': 'OG001'}, {'value': '-5.0', 'spread': '24.1', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '21.4', 'groupId': 'OG003'}, {'value': '-4.6', 'spread': '18.9', 'groupId': 'OG004'}, {'value': '-3.4', 'spread': '19.7', 'groupId': 'OG005'}]}]}, {'title': 'Lactate Dehydrogenase Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-4.9', 'spread': '26.4', 'groupId': 'OG000'}, {'value': '-2.5', 'spread': '25.2', 'groupId': 'OG001'}, {'value': '-3.5', 'spread': '22.1', 'groupId': 'OG002'}, {'value': '0.4', 'spread': '27.6', 'groupId': 'OG003'}, {'value': '-7.6', 'spread': '27.4', 'groupId': 'OG004'}, {'value': '-5.1', 'spread': '20.1', 'groupId': 'OG005'}]}]}, {'title': 'Lactate Dehydrogenase Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-4.9', 'spread': '22.4', 'groupId': 'OG000'}, {'value': '1.7', 'spread': '31.9', 'groupId': 'OG001'}, {'value': '-8.1', 'spread': '16.7', 'groupId': 'OG002'}, {'value': '5.0', 'spread': '43.5', 'groupId': 'OG003'}, {'value': '-4.5', 'spread': '37.7', 'groupId': 'OG004'}, {'value': '-4.4', 'spread': '15.4', 'groupId': 'OG005'}]}]}, {'title': 'Lactate Dehydrogenase Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-5.0', 'spread': '27.7', 'groupId': 'OG000'}, {'value': '-1.4', 'spread': '25.2', 'groupId': 'OG001'}, {'value': '-7.3', 'spread': '20.3', 'groupId': 'OG002'}, {'value': '2.0', 'spread': '16.2', 'groupId': 'OG003'}, {'value': '-11.0', 'spread': '27.5', 'groupId': 'OG004'}, {'value': '-3.5', 'spread': '22.6', 'groupId': 'OG005'}]}]}, {'title': 'Lactate Dehydrogenase Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-5.5', 'spread': '27.4', 'groupId': 'OG000'}, {'value': '0.5', 'spread': '25.2', 'groupId': 'OG001'}, {'value': '-12.3', 'spread': '22.2', 'groupId': 'OG002'}, {'value': '-0.8', 'spread': '18.9', 'groupId': 'OG003'}, {'value': '-10.7', 'spread': '33.1', 'groupId': 'OG004'}, {'value': '-3.7', 'spread': '27.5', 'groupId': 'OG005'}]}]}, {'title': 'Lactate Dehydrogenase Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-4.9', 'spread': '28.1', 'groupId': 'OG000'}, {'value': '2.9', 'spread': '26.7', 'groupId': 'OG001'}, {'value': '-7.5', 'spread': '25.1', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '20.6', 'groupId': 'OG003'}, {'value': '-5.6', 'spread': '33.1', 'groupId': 'OG004'}, {'value': '-4.4', 'spread': '24.8', 'groupId': 'OG005'}]}]}, {'title': 'Lactate Dehydrogenase SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '12.9', 'groupId': 'OG000'}, {'value': '-5.0', 'spread': '18.4', 'groupId': 'OG001'}, {'value': '3.3', 'spread': '81.2', 'groupId': 'OG002'}, {'value': '-45.5', 'spread': '16.3', 'groupId': 'OG003'}, {'value': '15.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '32.3', 'spread': '34.2', 'groupId': 'OG005'}]}]}, {'title': 'Alkaline Phosphatase Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.8', 'spread': '6.3', 'groupId': 'OG000'}, {'value': '-0.5', 'spread': '6.0', 'groupId': 'OG001'}, {'value': '-3.5', 'spread': '8.2', 'groupId': 'OG002'}, {'value': '-3.8', 'spread': '7.7', 'groupId': 'OG003'}, {'value': '-1.9', 'spread': '5.3', 'groupId': 'OG004'}, {'value': '-2.3', 'spread': '5.7', 'groupId': 'OG005'}]}]}, {'title': 'Alkaline Phosphatase Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-3.0', 'spread': '12.7', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '7.4', 'groupId': 'OG001'}, {'value': '-2.5', 'spread': '10.5', 'groupId': 'OG002'}, {'value': '-2.7', 'spread': '8.2', 'groupId': 'OG003'}, {'value': '-1.6', 'spread': '6.5', 'groupId': 'OG004'}, {'value': '-1.7', 'spread': '7.7', 'groupId': 'OG005'}]}]}, {'title': 'Alkaline Phosphatase Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.4', 'spread': '8.7', 'groupId': 'OG000'}, {'value': '-1.9', 'spread': '9.2', 'groupId': 'OG001'}, {'value': '-6.2', 'spread': '9.8', 'groupId': 'OG002'}, {'value': '-4.3', 'spread': '9.4', 'groupId': 'OG003'}, {'value': '-2.6', 'spread': '8.1', 'groupId': 'OG004'}, {'value': '-1.7', 'spread': '7.8', 'groupId': 'OG005'}]}]}, {'title': 'Alkaline Phosphatase Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-3.0', 'spread': '8.3', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '9.0', 'groupId': 'OG001'}, {'value': '-5.5', 'spread': '10.0', 'groupId': 'OG002'}, {'value': '-2.4', 'spread': '8.6', 'groupId': 'OG003'}, {'value': '-2.1', 'spread': '9.6', 'groupId': 'OG004'}, {'value': '-1.4', 'spread': '7.5', 'groupId': 'OG005'}]}]}, {'title': 'Alkaline Phosphatase Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-4.3', 'spread': '12.2', 'groupId': 'OG000'}, {'value': '-1.7', 'spread': '8.0', 'groupId': 'OG001'}, {'value': '-4.2', 'spread': '11.2', 'groupId': 'OG002'}, {'value': '-2.1', 'spread': '10.0', 'groupId': 'OG003'}, {'value': '-1.1', 'spread': '11.3', 'groupId': 'OG004'}, {'value': '-1.9', 'spread': '7.2', 'groupId': 'OG005'}]}]}, {'title': 'Alkaline Phosphatase Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.0', 'spread': '8.1', 'groupId': 'OG000'}, {'value': '0.3', 'spread': '7.2', 'groupId': 'OG001'}, {'value': '-2.4', 'spread': '11.8', 'groupId': 'OG002'}, {'value': '-0.4', 'spread': '9.0', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '10.4', 'groupId': 'OG004'}, {'value': '-0.4', 'spread': '8.4', 'groupId': 'OG005'}]}]}, {'title': 'Alkaline Phosphatase SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.5', 'spread': '7.4', 'groupId': 'OG000'}, {'value': '9.8', 'spread': '8.9', 'groupId': 'OG001'}, {'value': '7.8', 'spread': '15.3', 'groupId': 'OG002'}, {'value': '-3.0', 'spread': '5.7', 'groupId': 'OG003'}, {'value': '3.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '3.0', 'spread': '1.0', 'groupId': 'OG005'}]}]}, {'title': 'Alanine Aminotransferase Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '2.0', 'spread': '7.7', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '10.4', 'groupId': 'OG001'}, {'value': '-1.7', 'spread': '13.7', 'groupId': 'OG002'}, {'value': '1.6', 'spread': '12.2', 'groupId': 'OG003'}, {'value': '0.7', 'spread': '8.9', 'groupId': 'OG004'}, {'value': '1.2', 'spread': '9.1', 'groupId': 'OG005'}]}]}, {'title': 'Alanine Aminotransferase Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '6.5', 'groupId': 'OG000'}, {'value': '1.9', 'spread': '9.0', 'groupId': 'OG001'}, {'value': '2.0', 'spread': '29.8', 'groupId': 'OG002'}, {'value': '-0.9', 'spread': '7.7', 'groupId': 'OG003'}, {'value': '-0.2', 'spread': '10.2', 'groupId': 'OG004'}, {'value': '1.6', 'spread': '11.5', 'groupId': 'OG005'}]}]}, {'title': 'Alanine Aminotransferase Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.2', 'spread': '7.0', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '8.6', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '18.7', 'groupId': 'OG002'}, {'value': '-0.4', 'spread': '10.2', 'groupId': 'OG003'}, {'value': '0.4', 'spread': '14.7', 'groupId': 'OG004'}, {'value': '1.0', 'spread': '13.3', 'groupId': 'OG005'}]}]}, {'title': 'Alanine Aminotransferase Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '3.9', 'spread': '18.9', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '8.9', 'groupId': 'OG001'}, {'value': '-0.6', 'spread': '11.7', 'groupId': 'OG002'}, {'value': '3.5', 'spread': '20.9', 'groupId': 'OG003'}, {'value': '-1.7', 'spread': '13.7', 'groupId': 'OG004'}, {'value': '1.1', 'spread': '12.5', 'groupId': 'OG005'}]}]}, {'title': 'Alanine Aminotransferase Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '10.8', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '10.2', 'groupId': 'OG001'}, {'value': '0.1', 'spread': '10.5', 'groupId': 'OG002'}, {'value': '-0.4', 'spread': '9.7', 'groupId': 'OG003'}, {'value': '-1.1', 'spread': '14.5', 'groupId': 'OG004'}, {'value': '0.8', 'spread': '9.0', 'groupId': 'OG005'}]}]}, {'title': 'Alanine Aminotransferase Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '7.5', 'groupId': 'OG000'}, {'value': '1.8', 'spread': '9.9', 'groupId': 'OG001'}, {'value': '-1.0', 'spread': '10.8', 'groupId': 'OG002'}, {'value': '-0.9', 'spread': '9.1', 'groupId': 'OG003'}, {'value': '-0.9', 'spread': '14.6', 'groupId': 'OG004'}, {'value': '-0.4', 'spread': '10.6', 'groupId': 'OG005'}]}]}, {'title': 'Alanine Aminotransferase SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-3.8', 'spread': '3.0', 'groupId': 'OG000'}, {'value': '4.3', 'spread': '3.4', 'groupId': 'OG001'}, {'value': '26.5', 'spread': '42.1', 'groupId': 'OG002'}, {'value': '-6.0', 'spread': '8.5', 'groupId': 'OG003'}, {'value': '16.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-3.3', 'spread': '3.1', 'groupId': 'OG005'}]}]}, {'title': 'Aspartate Aminotransferase Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.5', 'spread': '6.1', 'groupId': 'OG000'}, {'value': '2.0', 'spread': '10.8', 'groupId': 'OG001'}, {'value': '-3.0', 'spread': '15.2', 'groupId': 'OG002'}, {'value': '1.9', 'spread': '11.5', 'groupId': 'OG003'}, {'value': '0.3', 'spread': '6.3', 'groupId': 'OG004'}, {'value': '-0.5', 'spread': '7.2', 'groupId': 'OG005'}]}]}, {'title': 'Aspartate Aminotransferase Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.0', 'spread': '3.8', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '4.9', 'groupId': 'OG001'}, {'value': '-1.9', 'spread': '19.1', 'groupId': 'OG002'}, {'value': '-0.9', 'spread': '4.7', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '6.1', 'groupId': 'OG004'}, {'value': '0.9', 'spread': '13.4', 'groupId': 'OG005'}]}]}, {'title': 'Aspartate Aminotransferase Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '4.8', 'groupId': 'OG000'}, {'value': '-0.1', 'spread': '5.8', 'groupId': 'OG001'}, {'value': '-2.5', 'spread': '17.5', 'groupId': 'OG002'}, {'value': '-0.4', 'spread': '5.9', 'groupId': 'OG003'}, {'value': '0.6', 'spread': '8.2', 'groupId': 'OG004'}, {'value': '-0.4', 'spread': '7.5', 'groupId': 'OG005'}]}]}, {'title': 'Aspartate Aminotransferase Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.5', 'spread': '10.6', 'groupId': 'OG000'}, {'value': '0.8', 'spread': '6.0', 'groupId': 'OG001'}, {'value': '-0.9', 'spread': '9.5', 'groupId': 'OG002'}, {'value': '4.0', 'spread': '15.7', 'groupId': 'OG003'}, {'value': '-1.4', 'spread': '7.0', 'groupId': 'OG004'}, {'value': '-1.4', 'spread': '6.5', 'groupId': 'OG005'}]}]}, {'title': 'Aspartate Aminotransferase Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '5.1', 'groupId': 'OG000'}, {'value': '0.2', 'spread': '6.7', 'groupId': 'OG001'}, {'value': '-1.4', 'spread': '5.4', 'groupId': 'OG002'}, {'value': '-1.4', 'spread': '4.6', 'groupId': 'OG003'}, {'value': '-0.4', 'spread': '8.3', 'groupId': 'OG004'}, {'value': '-0.8', 'spread': '6.3', 'groupId': 'OG005'}]}]}, {'title': 'Aspartate Aminotransferase Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '5.5', 'groupId': 'OG000'}, {'value': '1.1', 'spread': '7.9', 'groupId': 'OG001'}, {'value': '-1.4', 'spread': '8.3', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '4.8', 'groupId': 'OG003'}, {'value': '-0.5', 'spread': '7.3', 'groupId': 'OG004'}, {'value': '-0.9', 'spread': '5.2', 'groupId': 'OG005'}]}]}, {'title': 'Aspartate Aminotransferase SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.8', 'spread': '1.7', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '2.1', 'groupId': 'OG001'}, {'value': '11.5', 'spread': '23.5', 'groupId': 'OG002'}, {'value': '-4.0', 'spread': '2.8', 'groupId': 'OG003'}, {'value': '9.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.7', 'spread': '2.5', 'groupId': 'OG005'}]}]}, {'title': 'Gamma Glutamyl Transferase Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '6.4', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '14.1', 'groupId': 'OG001'}, {'value': '-2.0', 'spread': '10.7', 'groupId': 'OG002'}, {'value': '-7.5', 'spread': '42.1', 'groupId': 'OG003'}, {'value': '1.6', 'spread': '22.9', 'groupId': 'OG004'}, {'value': '-0.8', 'spread': '6.3', 'groupId': 'OG005'}]}]}, {'title': 'Gamma Glutamyl Transferase Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.2', 'spread': '8.7', 'groupId': 'OG000'}, {'value': '-1.6', 'spread': '11.1', 'groupId': 'OG001'}, {'value': '0.2', 'spread': '14.2', 'groupId': 'OG002'}, {'value': '-1.2', 'spread': '8.0', 'groupId': 'OG003'}, {'value': '-1.9', 'spread': '6.5', 'groupId': 'OG004'}, {'value': '0.4', 'spread': '15.0', 'groupId': 'OG005'}]}]}, {'title': 'Gamma Glutamyl Transferase Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.7', 'spread': '8.5', 'groupId': 'OG000'}, {'value': '-1.9', 'spread': '11.8', 'groupId': 'OG001'}, {'value': '1.8', 'spread': '18.6', 'groupId': 'OG002'}, {'value': '-2.6', 'spread': '12.8', 'groupId': 'OG003'}, {'value': '-0.4', 'spread': '8.4', 'groupId': 'OG004'}, {'value': '-1.4', 'spread': '14.1', 'groupId': 'OG005'}]}]}, {'title': 'Gamma Glutamyl Transferase Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.8', 'spread': '10.5', 'groupId': 'OG000'}, {'value': '-1.8', 'spread': '13.8', 'groupId': 'OG001'}, {'value': '-2.9', 'spread': '13.1', 'groupId': 'OG002'}, {'value': '-2.9', 'spread': '7.3', 'groupId': 'OG003'}, {'value': '-2.1', 'spread': '9.3', 'groupId': 'OG004'}, {'value': '-1.1', 'spread': '12.9', 'groupId': 'OG005'}]}]}, {'title': 'Gamma Glutamyl Transferase Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '2.4', 'spread': '13.7', 'groupId': 'OG000'}, {'value': '-1.9', 'spread': '14.9', 'groupId': 'OG001'}, {'value': '-0.9', 'spread': '18.4', 'groupId': 'OG002'}, {'value': '-2.6', 'spread': '13.6', 'groupId': 'OG003'}, {'value': '-2.5', 'spread': '9.4', 'groupId': 'OG004'}, {'value': '3.1', 'spread': '29.5', 'groupId': 'OG005'}]}]}, {'title': 'Gamma Glutamyl Transferase Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '10.9', 'groupId': 'OG000'}, {'value': '-2.2', 'spread': '13.3', 'groupId': 'OG001'}, {'value': '-1.1', 'spread': '21.7', 'groupId': 'OG002'}, {'value': '-0.6', 'spread': '11.2', 'groupId': 'OG003'}, {'value': '-0.4', 'spread': '11.1', 'groupId': 'OG004'}, {'value': '-0.9', 'spread': '12.2', 'groupId': 'OG005'}]}]}, {'title': 'Gamma Glutamyl Transferase SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-8.0', 'spread': '13.4', 'groupId': 'OG000'}, {'value': '1.3', 'spread': '3.9', 'groupId': 'OG001'}, {'value': '19.8', 'spread': '23.3', 'groupId': 'OG002'}, {'value': '-16.5', 'spread': '24.7', 'groupId': 'OG003'}, {'value': '37.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '3.0', 'spread': '3.5', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase were measured in units per liter (U/L).', 'unitOfMeasure': 'U/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Creatinine Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.6', 'spread': '7.0', 'groupId': 'OG000'}, {'value': '2.7', 'spread': '10.1', 'groupId': 'OG001'}, {'value': '1.4', 'spread': '8.6', 'groupId': 'OG002'}, {'value': '0.6', 'spread': '8.1', 'groupId': 'OG003'}, {'value': '0.7', 'spread': '8.4', 'groupId': 'OG004'}, {'value': '-0.7', 'spread': '7.7', 'groupId': 'OG005'}]}]}, {'title': 'Creatinine Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '7.1', 'groupId': 'OG000'}, {'value': '-0.8', 'spread': '8.2', 'groupId': 'OG001'}, {'value': '-0.4', 'spread': '10.1', 'groupId': 'OG002'}, {'value': '-0.7', 'spread': '8.5', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '8.3', 'groupId': 'OG004'}, {'value': '0.0', 'spread': '7.1', 'groupId': 'OG005'}]}]}, {'title': 'Creatinine Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.0', 'spread': '5.8', 'groupId': 'OG000'}, {'value': '1.3', 'spread': '9.1', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '7.9', 'groupId': 'OG002'}, {'value': '-1.7', 'spread': '8.1', 'groupId': 'OG003'}, {'value': '0.6', 'spread': '8.1', 'groupId': 'OG004'}, {'value': '1.6', 'spread': '7.2', 'groupId': 'OG005'}]}]}, {'title': 'Creatinine Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '7.8', 'groupId': 'OG000'}, {'value': '1.6', 'spread': '10.5', 'groupId': 'OG001'}, {'value': '-0.1', 'spread': '10.6', 'groupId': 'OG002'}, {'value': '-0.6', 'spread': '7.9', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '8.1', 'groupId': 'OG004'}, {'value': '-0.5', 'spread': '11.1', 'groupId': 'OG005'}]}]}, {'title': 'Creatinine Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '6.2', 'groupId': 'OG000'}, {'value': '-0.4', 'spread': '7.4', 'groupId': 'OG001'}, {'value': '-1.0', 'spread': '9.6', 'groupId': 'OG002'}, {'value': '-2.6', 'spread': '8.4', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '7.6', 'groupId': 'OG004'}, {'value': '0.1', 'spread': '8.3', 'groupId': 'OG005'}]}]}, {'title': 'Creatinine Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.6', 'spread': '7.8', 'groupId': 'OG000'}, {'value': '-0.2', 'spread': '7.0', 'groupId': 'OG001'}, {'value': '0.7', 'spread': '12.0', 'groupId': 'OG002'}, {'value': '-0.7', 'spread': '9.1', 'groupId': 'OG003'}, {'value': '0.1', 'spread': '9.0', 'groupId': 'OG004'}, {'value': '-0.7', 'spread': '7.2', 'groupId': 'OG005'}]}]}, {'title': 'Creatinine SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.5', 'spread': '4.4', 'groupId': 'OG000'}, {'value': '6.0', 'spread': '4.3', 'groupId': 'OG001'}, {'value': '-6.5', 'spread': '4.4', 'groupId': 'OG002'}, {'value': '-10.5', 'spread': '16.3', 'groupId': 'OG003'}, {'value': '9.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '1.3', 'spread': '6.4', 'groupId': 'OG005'}]}]}, {'title': 'Bilirubin Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.53', 'spread': '3.10', 'groupId': 'OG000'}, {'value': '-1.79', 'spread': '4.50', 'groupId': 'OG001'}, {'value': '-0.52', 'spread': '2.81', 'groupId': 'OG002'}, {'value': '-0.55', 'spread': '4.49', 'groupId': 'OG003'}, {'value': '0.57', 'spread': '5.73', 'groupId': 'OG004'}, {'value': '0.14', 'spread': '4.16', 'groupId': 'OG005'}]}]}, {'title': 'Bilirubin Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.35', 'spread': '2.85', 'groupId': 'OG000'}, {'value': '-0.86', 'spread': '5.05', 'groupId': 'OG001'}, {'value': '-0.48', 'spread': '3.40', 'groupId': 'OG002'}, {'value': '-0.38', 'spread': '3.60', 'groupId': 'OG003'}, {'value': '-0.99', 'spread': '2.98', 'groupId': 'OG004'}, {'value': '0.27', 'spread': '3.69', 'groupId': 'OG005'}]}]}, {'title': 'Bilirubin Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.70', 'spread': '3.26', 'groupId': 'OG000'}, {'value': '-1.70', 'spread': '4.92', 'groupId': 'OG001'}, {'value': '-0.26', 'spread': '3.53', 'groupId': 'OG002'}, {'value': '-0.04', 'spread': '2.74', 'groupId': 'OG003'}, {'value': '0.76', 'spread': '4.27', 'groupId': 'OG004'}, {'value': '0.70', 'spread': '4.52', 'groupId': 'OG005'}]}]}, {'title': 'Bilirubin Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.51', 'spread': '3.13', 'groupId': 'OG000'}, {'value': '-1.15', 'spread': '4.59', 'groupId': 'OG001'}, {'value': '0.35', 'spread': '3.44', 'groupId': 'OG002'}, {'value': '-0.33', 'spread': '3.94', 'groupId': 'OG003'}, {'value': '0.11', 'spread': '4.19', 'groupId': 'OG004'}, {'value': '-0.30', 'spread': '4.28', 'groupId': 'OG005'}]}]}, {'title': 'Bilirubin Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.21', 'spread': '3.81', 'groupId': 'OG000'}, {'value': '-0.98', 'spread': '4.68', 'groupId': 'OG001'}, {'value': '-0.30', 'spread': '3.20', 'groupId': 'OG002'}, {'value': '-0.43', 'spread': '4.52', 'groupId': 'OG003'}, {'value': '-0.15', 'spread': '3.79', 'groupId': 'OG004'}, {'value': '-0.02', 'spread': '4.41', 'groupId': 'OG005'}]}]}, {'title': 'Bilirubin Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.74', 'spread': '3.43', 'groupId': 'OG000'}, {'value': '-1.02', 'spread': '5.24', 'groupId': 'OG001'}, {'value': '-0.73', 'spread': '2.98', 'groupId': 'OG002'}, {'value': '-1.20', 'spread': '3.37', 'groupId': 'OG003'}, {'value': '-0.43', 'spread': '3.68', 'groupId': 'OG004'}, {'value': '-0.34', 'spread': '3.45', 'groupId': 'OG005'}]}]}, {'title': 'Bilirubin SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '2.05', 'spread': '2.16', 'groupId': 'OG000'}, {'value': '-1.23', 'spread': '2.62', 'groupId': 'OG001'}, {'value': '-0.30', 'spread': '3.87', 'groupId': 'OG002'}, {'value': '-0.25', 'spread': '0.78', 'groupId': 'OG003'}, {'value': '-1.50', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '1.40', 'spread': '2.96', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Creatinine and bilirubin were measured in micromols per liter (μmol/L).', 'unitOfMeasure': 'μmol/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '12', 'groupId': 'OG004'}, {'value': '10', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.110', 'spread': '5.255', 'groupId': 'OG000'}, {'value': '-5.367', 'spread': '11.806', 'groupId': 'OG001'}, {'value': '-0.775', 'spread': '2.020', 'groupId': 'OG002'}, {'value': '-2.635', 'spread': '2.550', 'groupId': 'OG003'}, {'value': '-5.108', 'spread': '10.013', 'groupId': 'OG004'}, {'value': '-3.732', 'spread': '3.997', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '9', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}, {'value': '9', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.821', 'spread': '6.974', 'groupId': 'OG000'}, {'value': '-6.985', 'spread': '11.064', 'groupId': 'OG001'}, {'value': '0.576', 'spread': '2.898', 'groupId': 'OG002'}, {'value': '2.743', 'spread': '15.212', 'groupId': 'OG003'}, {'value': '-6.763', 'spread': '13.211', 'groupId': 'OG004'}, {'value': '-3.042', 'spread': '1.989', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '10', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.338', 'spread': '11.182', 'groupId': 'OG000'}, {'value': '-5.835', 'spread': '8.594', 'groupId': 'OG001'}, {'value': '-1.722', 'spread': '5.596', 'groupId': 'OG002'}, {'value': '0.929', 'spread': '8.047', 'groupId': 'OG003'}, {'value': '-4.226', 'spread': '9.865', 'groupId': 'OG004'}, {'value': '7.141', 'spread': '32.344', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '2.978', 'spread': '13.162', 'groupId': 'OG000'}, {'value': '-5.930', 'spread': '9.560', 'groupId': 'OG001'}, {'value': '-4.516', 'spread': '11.304', 'groupId': 'OG002'}, {'value': '-0.595', 'spread': '7.346', 'groupId': 'OG003'}, {'value': '1.799', 'spread': '14.635', 'groupId': 'OG004'}, {'value': '-6.598', 'spread': '6.278', 'groupId': 'OG005'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '12', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}, {'value': '7', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '3.153', 'spread': '18.764', 'groupId': 'OG000'}, {'value': '-6.891', 'spread': '15.192', 'groupId': 'OG001'}, {'value': '-3.143', 'spread': '10.844', 'groupId': 'OG002'}, {'value': '2.590', 'spread': '7.755', 'groupId': 'OG003'}, {'value': '12.434', 'spread': '47.447', 'groupId': 'OG004'}, {'value': '-1.104', 'spread': '5.201', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '4', 'groupId': 'OG003'}, {'value': '8', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '7.279', 'spread': '13.546', 'groupId': 'OG000'}, {'value': '-5.193', 'spread': '10.817', 'groupId': 'OG001'}, {'value': '0.695', 'spread': '6.381', 'groupId': 'OG002'}, {'value': '-3.033', 'spread': '7.261', 'groupId': 'OG003'}, {'value': '-9.890', 'spread': '10.729', 'groupId': 'OG004'}, {'value': '-5.368', 'spread': '5.322', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '8.000', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'C Reactive Protein was measured in milligrams per liters (mg/L).', 'unitOfMeasure': 'mg/L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (pH)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '-0.10', 'spread': '0.79', 'groupId': 'OG001'}, {'value': '-0.13', 'spread': '0.88', 'groupId': 'OG002'}, {'value': '-0.20', 'spread': '0.88', 'groupId': 'OG003'}, {'value': '-0.08', 'spread': '0.82', 'groupId': 'OG004'}, {'value': '-0.07', 'spread': '0.90', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '39', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.06', 'spread': '0.86', 'groupId': 'OG000'}, {'value': '-0.06', 'spread': '0.86', 'groupId': 'OG001'}, {'value': '-0.10', 'spread': '0.77', 'groupId': 'OG002'}, {'value': '-0.23', 'spread': '0.92', 'groupId': 'OG003'}, {'value': '-0.18', 'spread': '0.76', 'groupId': 'OG004'}, {'value': '0.06', 'spread': '0.65', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.87', 'groupId': 'OG000'}, {'value': '-0.09', 'spread': '0.76', 'groupId': 'OG001'}, {'value': '-0.11', 'spread': '0.95', 'groupId': 'OG002'}, {'value': '-0.26', 'spread': '0.89', 'groupId': 'OG003'}, {'value': '-0.07', 'spread': '0.73', 'groupId': 'OG004'}, {'value': '-0.04', 'spread': '0.74', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.01', 'spread': '0.73', 'groupId': 'OG000'}, {'value': '-0.03', 'spread': '0.68', 'groupId': 'OG001'}, {'value': '-0.17', 'spread': '0.69', 'groupId': 'OG002'}, {'value': '-0.18', 'spread': '0.86', 'groupId': 'OG003'}, {'value': '-0.13', 'spread': '0.81', 'groupId': 'OG004'}, {'value': '0.05', 'spread': '0.86', 'groupId': 'OG005'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.92', 'groupId': 'OG000'}, {'value': '-0.07', 'spread': '0.83', 'groupId': 'OG001'}, {'value': '-0.12', 'spread': '1.07', 'groupId': 'OG002'}, {'value': '-0.34', 'spread': '0.79', 'groupId': 'OG003'}, {'value': '-0.30', 'spread': '0.91', 'groupId': 'OG004'}, {'value': '0.08', 'spread': '0.75', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.14', 'spread': '0.79', 'groupId': 'OG000'}, {'value': '-0.01', 'spread': '0.85', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.70', 'groupId': 'OG002'}, {'value': '-0.28', 'spread': '0.85', 'groupId': 'OG003'}, {'value': '-0.21', 'spread': '0.99', 'groupId': 'OG004'}, {'value': '-0.01', 'spread': '0.85', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.25', 'spread': '1.04', 'groupId': 'OG000'}, {'value': '-0.25', 'spread': '0.87', 'groupId': 'OG001'}, {'value': '0.50', 'spread': '1.22', 'groupId': 'OG002'}, {'value': '-1.00', 'spread': '1.41', 'groupId': 'OG003'}, {'value': '0.50', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-0.17', 'spread': '0.29', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Urine pH was measured on a pH scale.', 'unitOfMeasure': 'ph', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Leukocyte Esterase)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Baseline Low - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 Normal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Normal', 'categories': [{'measurements': [{'value': '84.6', 'groupId': 'OG000'}, {'value': '84.2', 'groupId': 'OG001'}, {'value': '97.3', 'groupId': 'OG002'}, {'value': '88.2', 'groupId': 'OG003'}, {'value': '90.0', 'groupId': 'OG004'}, {'value': '92.3', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 High', 'categories': [{'measurements': [{'value': '2.6', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2.7', 'groupId': 'OG002'}, {'value': '5.9', 'groupId': 'OG003'}, {'value': '5.0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Normal', 'categories': [{'measurements': [{'value': '7.7', 'groupId': 'OG000'}, {'value': '15.8', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2.9', 'groupId': 'OG003'}, {'value': '5.0', 'groupId': 'OG004'}, {'value': '7.7', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 High', 'categories': [{'measurements': [{'value': '5.1', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2.9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.\n\nNumber of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Nitrite)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Baseline Low - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 Normal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Normal', 'categories': [{'measurements': [{'value': '97.4', 'groupId': 'OG000'}, {'value': '97.4', 'groupId': 'OG001'}, {'value': '100', 'groupId': 'OG002'}, {'value': '100', 'groupId': 'OG003'}, {'value': '95.0', 'groupId': 'OG004'}, {'value': '94.9', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2.6', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2.5', 'groupId': 'OG004'}, {'value': '2.6', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Normal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '2.6', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 High', 'categories': [{'measurements': [{'value': '2.6', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2.5', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.\n\nNumber of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Occult Blood)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Baseline Low - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 Normal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Normal', 'categories': [{'measurements': [{'value': '76.9', 'groupId': 'OG000'}, {'value': '86.8', 'groupId': 'OG001'}, {'value': '83.8', 'groupId': 'OG002'}, {'value': '79.4', 'groupId': 'OG003'}, {'value': '77.5', 'groupId': 'OG004'}, {'value': '89.7', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '5.3', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '5.9', 'groupId': 'OG003'}, {'value': '5.0', 'groupId': 'OG004'}, {'value': '2.6', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Normal', 'categories': [{'measurements': [{'value': '10.3', 'groupId': 'OG000'}, {'value': '5.3', 'groupId': 'OG001'}, {'value': '5.4', 'groupId': 'OG002'}, {'value': '8.8', 'groupId': 'OG003'}, {'value': '15.0', 'groupId': 'OG004'}, {'value': '5.1', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 High', 'categories': [{'measurements': [{'value': '12.8', 'groupId': 'OG000'}, {'value': '2.6', 'groupId': 'OG001'}, {'value': '10.8', 'groupId': 'OG002'}, {'value': '5.9', 'groupId': 'OG003'}, {'value': '2.5', 'groupId': 'OG004'}, {'value': '2.6', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.\n\nNumber of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Urine Glucose)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Baseline Low - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 Normal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Normal', 'categories': [{'measurements': [{'value': '94.9', 'groupId': 'OG000'}, {'value': '94.7', 'groupId': 'OG001'}, {'value': '97.3', 'groupId': 'OG002'}, {'value': '97.1', 'groupId': 'OG003'}, {'value': '95.0', 'groupId': 'OG004'}, {'value': '94.9', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '2.6', 'groupId': 'OG001'}, {'value': '2.7', 'groupId': 'OG002'}, {'value': '2.9', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Normal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2.5', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 High', 'categories': [{'measurements': [{'value': '5.1', 'groupId': 'OG000'}, {'value': '2.6', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '2.5', 'groupId': 'OG004'}, {'value': '5.1', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.\n\nNumber of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Albumin)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '37', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Baseline Low - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 Normal', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Low - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 Normal', 'categories': [{'measurements': [{'value': '94.9', 'groupId': 'OG000'}, {'value': '89.5', 'groupId': 'OG001'}, {'value': '86.5', 'groupId': 'OG002'}, {'value': '91.2', 'groupId': 'OG003'}, {'value': '95.0', 'groupId': 'OG004'}, {'value': '92.3', 'groupId': 'OG005'}]}]}, {'title': 'Baseline Normal - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '7.9', 'groupId': 'OG001'}, {'value': '2.7', 'groupId': 'OG002'}, {'value': '2.9', 'groupId': 'OG003'}, {'value': '2.5', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Low', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 Normal', 'categories': [{'measurements': [{'value': '5.1', 'groupId': 'OG000'}, {'value': '2.6', 'groupId': 'OG001'}, {'value': '10.8', 'groupId': 'OG002'}, {'value': '5.9', 'groupId': 'OG003'}, {'value': '2.5', 'groupId': 'OG004'}, {'value': '2.6', 'groupId': 'OG005'}]}]}, {'title': 'Baseline High - Week 12 High', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '5.1', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.\n\nNumber of participants reflect those with non-missing urinalysis results at Baseline and at Week 12.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Systolic Blood Pressure Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '10.7', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '7.1', 'groupId': 'OG001'}, {'value': '-3.9', 'spread': '8.3', 'groupId': 'OG002'}, {'value': '1.7', 'spread': '9.3', 'groupId': 'OG003'}, {'value': '0.2', 'spread': '12.1', 'groupId': 'OG004'}, {'value': '-1.0', 'spread': '9.9', 'groupId': 'OG005'}]}]}, {'title': 'Systolic Blood Pressure Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '9.7', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '9.4', 'groupId': 'OG001'}, {'value': '-2.7', 'spread': '12.5', 'groupId': 'OG002'}, {'value': '0.2', 'spread': '13.6', 'groupId': 'OG003'}, {'value': '-0.6', 'spread': '8.4', 'groupId': 'OG004'}, {'value': '-3.2', 'spread': '11.2', 'groupId': 'OG005'}]}]}, {'title': 'Systolic Blood Pressure Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '10.0', 'groupId': 'OG000'}, {'value': '2.1', 'spread': '7.9', 'groupId': 'OG001'}, {'value': '-1.9', 'spread': '11.3', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '12.4', 'groupId': 'OG003'}, {'value': '-0.1', 'spread': '11.3', 'groupId': 'OG004'}, {'value': '-0.5', 'spread': '10.8', 'groupId': 'OG005'}]}]}, {'title': 'Systolic Blood Pressure Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.4', 'spread': '9.8', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '10.7', 'groupId': 'OG001'}, {'value': '-4.3', 'spread': '10.6', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '12.8', 'groupId': 'OG003'}, {'value': '-0.9', 'spread': '10.9', 'groupId': 'OG004'}, {'value': '-2.4', 'spread': '9.2', 'groupId': 'OG005'}]}]}, {'title': 'Systolic Blood Pressure Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.8', 'spread': '12.1', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '13.0', 'groupId': 'OG001'}, {'value': '-3.4', 'spread': '8.0', 'groupId': 'OG002'}, {'value': '0.1', 'spread': '12.3', 'groupId': 'OG003'}, {'value': '0.5', 'spread': '12.5', 'groupId': 'OG004'}, {'value': '-1.0', 'spread': '10.7', 'groupId': 'OG005'}]}]}, {'title': 'Systolic Blood Pressure Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.3', 'spread': '10.9', 'groupId': 'OG000'}, {'value': '2.2', 'spread': '9.0', 'groupId': 'OG001'}, {'value': '-2.9', 'spread': '10.3', 'groupId': 'OG002'}, {'value': '-0.3', 'spread': '11.8', 'groupId': 'OG003'}, {'value': '-1.2', 'spread': '10.4', 'groupId': 'OG004'}, {'value': '-2.4', 'spread': '10.1', 'groupId': 'OG005'}]}]}, {'title': 'Systolic Blood Pressure SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-7.0', 'spread': '12.7', 'groupId': 'OG000'}, {'value': '-10.5', 'spread': '17.0', 'groupId': 'OG001'}, {'value': '-1.3', 'spread': '10.4', 'groupId': 'OG002'}, {'value': '4.5', 'spread': '7.8', 'groupId': 'OG003'}, {'value': '-2.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-2.0', 'spread': '2.6', 'groupId': 'OG005'}]}]}, {'title': 'Diastolic Blood Pressure Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.4', 'spread': '7.4', 'groupId': 'OG000'}, {'value': '0.9', 'spread': '10.0', 'groupId': 'OG001'}, {'value': '-2.1', 'spread': '7.3', 'groupId': 'OG002'}, {'value': '0.6', 'spread': '6.5', 'groupId': 'OG003'}, {'value': '0.3', 'spread': '7.4', 'groupId': 'OG004'}, {'value': '0.1', 'spread': '6.7', 'groupId': 'OG005'}]}]}, {'title': 'Diastolic Blood Pressure Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.5', 'spread': '6.9', 'groupId': 'OG000'}, {'value': '0.4', 'spread': '8.7', 'groupId': 'OG001'}, {'value': '-1.2', 'spread': '7.1', 'groupId': 'OG002'}, {'value': '2.1', 'spread': '8.3', 'groupId': 'OG003'}, {'value': '0.0', 'spread': '7.2', 'groupId': 'OG004'}, {'value': '0.2', 'spread': '7.0', 'groupId': 'OG005'}]}]}, {'title': 'Diastolic Blood Pressure Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.3', 'spread': '7.8', 'groupId': 'OG000'}, {'value': '0.6', 'spread': '9.2', 'groupId': 'OG001'}, {'value': '-0.3', 'spread': '7.9', 'groupId': 'OG002'}, {'value': '0.6', 'spread': '7.3', 'groupId': 'OG003'}, {'value': '0.0', 'spread': '7.7', 'groupId': 'OG004'}, {'value': '0.3', 'spread': '8.1', 'groupId': 'OG005'}]}]}, {'title': 'Diastolic Blood Pressure Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.3', 'spread': '7.6', 'groupId': 'OG000'}, {'value': '0.0', 'spread': '9.7', 'groupId': 'OG001'}, {'value': '-3.1', 'spread': '7.9', 'groupId': 'OG002'}, {'value': '1.3', 'spread': '8.6', 'groupId': 'OG003'}, {'value': '0.1', 'spread': '7.3', 'groupId': 'OG004'}, {'value': '-1.6', 'spread': '7.3', 'groupId': 'OG005'}]}]}, {'title': 'Diastolic Blood Pressure Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-1.1', 'spread': '8.9', 'groupId': 'OG000'}, {'value': '-0.3', 'spread': '9.1', 'groupId': 'OG001'}, {'value': '-1.2', 'spread': '7.3', 'groupId': 'OG002'}, {'value': '2.8', 'spread': '8.7', 'groupId': 'OG003'}, {'value': '-0.7', 'spread': '7.7', 'groupId': 'OG004'}, {'value': '-0.6', 'spread': '8.2', 'groupId': 'OG005'}]}]}, {'title': 'Diastolic Blood Pressure Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.3', 'spread': '5.8', 'groupId': 'OG000'}, {'value': '0.5', 'spread': '6.3', 'groupId': 'OG001'}, {'value': '-1.7', 'spread': '6.4', 'groupId': 'OG002'}, {'value': '3.1', 'spread': '8.4', 'groupId': 'OG003'}, {'value': '-1.1', 'spread': '6.7', 'groupId': 'OG004'}, {'value': '-1.1', 'spread': '7.3', 'groupId': 'OG005'}]}]}, {'title': 'Diastolic Blood Pressure SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.3', 'spread': '8.5', 'groupId': 'OG000'}, {'value': '-9.0', 'spread': '9.1', 'groupId': 'OG001'}, {'value': '0.8', 'spread': '8.8', 'groupId': 'OG002'}, {'value': '-4.5', 'spread': '0.7', 'groupId': 'OG003'}, {'value': '-9.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '-4.0', 'spread': '6.6', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Blood pressure was measured in millimeters of mercury (mmHg).', 'unitOfMeasure': 'mmHg', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '9.5', 'groupId': 'OG000'}, {'value': '-1.6', 'spread': '9.1', 'groupId': 'OG001'}, {'value': '3.2', 'spread': '8.0', 'groupId': 'OG002'}, {'value': '-1.8', 'spread': '8.1', 'groupId': 'OG003'}, {'value': '0.1', 'spread': '6.4', 'groupId': 'OG004'}, {'value': '-0.4', 'spread': '7.7', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.2', 'spread': '8.4', 'groupId': 'OG000'}, {'value': '-1.3', 'spread': '9.9', 'groupId': 'OG001'}, {'value': '1.1', 'spread': '7.8', 'groupId': 'OG002'}, {'value': '-1.0', 'spread': '10.4', 'groupId': 'OG003'}, {'value': '-2.2', 'spread': '7.9', 'groupId': 'OG004'}, {'value': '0.5', 'spread': '9.5', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.0', 'spread': '10.2', 'groupId': 'OG000'}, {'value': '-3.1', 'spread': '9.9', 'groupId': 'OG001'}, {'value': '0.6', 'spread': '7.8', 'groupId': 'OG002'}, {'value': '-3.6', 'spread': '9.0', 'groupId': 'OG003'}, {'value': '-1.6', 'spread': '6.5', 'groupId': 'OG004'}, {'value': '1.6', 'spread': '8.0', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '9.8', 'groupId': 'OG000'}, {'value': '1.2', 'spread': '10.7', 'groupId': 'OG001'}, {'value': '1.4', 'spread': '8.3', 'groupId': 'OG002'}, {'value': '-2.6', 'spread': '9.7', 'groupId': 'OG003'}, {'value': '-1.7', 'spread': '9.3', 'groupId': 'OG004'}, {'value': '2.6', 'spread': '8.0', 'groupId': 'OG005'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '1.7', 'spread': '8.9', 'groupId': 'OG000'}, {'value': '-3.2', 'spread': '9.3', 'groupId': 'OG001'}, {'value': '0.4', 'spread': '9.2', 'groupId': 'OG002'}, {'value': '-1.8', 'spread': '8.5', 'groupId': 'OG003'}, {'value': '0.5', 'spread': '8.2', 'groupId': 'OG004'}, {'value': '0.6', 'spread': '6.7', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.9', 'spread': '8.4', 'groupId': 'OG000'}, {'value': '-1.9', 'spread': '6.8', 'groupId': 'OG001'}, {'value': '1.8', 'spread': '11.0', 'groupId': 'OG002'}, {'value': '-3.1', 'spread': '8.5', 'groupId': 'OG003'}, {'value': '-1.7', 'spread': '9.1', 'groupId': 'OG004'}, {'value': '0.0', 'spread': '7.5', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-2.8', 'spread': '2.6', 'groupId': 'OG000'}, {'value': '-2.5', 'spread': '12.0', 'groupId': 'OG001'}, {'value': '2.3', 'spread': '6.0', 'groupId': 'OG002'}, {'value': '1.5', 'spread': '4.9', 'groupId': 'OG003'}, {'value': '-7.0', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '7.3', 'spread': '3.2', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Pulse rate was measured in beats per minute (beats/min).', 'unitOfMeasure': 'beats/min', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline Until Safety Follow-up Visit in Vital Signs (Temperature)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.23', 'groupId': 'OG000'}, {'value': '-0.04', 'spread': '0.22', 'groupId': 'OG001'}, {'value': '0.02', 'spread': '0.30', 'groupId': 'OG002'}, {'value': '-0.11', 'spread': '0.32', 'groupId': 'OG003'}, {'value': '-0.07', 'spread': '0.30', 'groupId': 'OG004'}, {'value': '0.02', 'spread': '0.35', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.00', 'spread': '0.26', 'groupId': 'OG000'}, {'value': '0.02', 'spread': '0.26', 'groupId': 'OG001'}, {'value': '0.01', 'spread': '0.33', 'groupId': 'OG002'}, {'value': '0.01', 'spread': '0.35', 'groupId': 'OG003'}, {'value': '-0.04', 'spread': '0.36', 'groupId': 'OG004'}, {'value': '-0.01', 'spread': '0.35', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.05', 'spread': '0.29', 'groupId': 'OG000'}, {'value': '0.03', 'spread': '0.24', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.42', 'groupId': 'OG002'}, {'value': '-0.04', 'spread': '0.24', 'groupId': 'OG003'}, {'value': '-0.03', 'spread': '0.26', 'groupId': 'OG004'}, {'value': '-0.01', 'spread': '0.41', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '-0.03', 'spread': '0.29', 'groupId': 'OG000'}, {'value': '-0.02', 'spread': '0.25', 'groupId': 'OG001'}, {'value': '-0.01', 'spread': '0.22', 'groupId': 'OG002'}, {'value': '-0.06', 'spread': '0.43', 'groupId': 'OG003'}, {'value': '-0.03', 'spread': '0.38', 'groupId': 'OG004'}, {'value': '0.07', 'spread': '0.24', 'groupId': 'OG005'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.01', 'spread': '0.24', 'groupId': 'OG000'}, {'value': '-0.02', 'spread': '0.28', 'groupId': 'OG001'}, {'value': '0.00', 'spread': '0.33', 'groupId': 'OG002'}, {'value': '-0.03', 'spread': '0.41', 'groupId': 'OG003'}, {'value': '0.00', 'spread': '0.35', 'groupId': 'OG004'}, {'value': '0.02', 'spread': '0.31', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.10', 'spread': '0.27', 'groupId': 'OG000'}, {'value': '0.00', 'spread': '0.27', 'groupId': 'OG001'}, {'value': '0.06', 'spread': '0.36', 'groupId': 'OG002'}, {'value': '-0.04', 'spread': '0.28', 'groupId': 'OG003'}, {'value': '0.00', 'spread': '0.33', 'groupId': 'OG004'}, {'value': '0.00', 'spread': '0.30', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0.08', 'spread': '0.22', 'groupId': 'OG000'}, {'value': '0.15', 'spread': '0.33', 'groupId': 'OG001'}, {'value': '-0.03', 'spread': '0.05', 'groupId': 'OG002'}, {'value': '0.10', 'spread': '0.00', 'groupId': 'OG003'}, {'value': '0.10', 'spread': 'NA', 'comment': 'Value was not evaluable because only one participant was analyzed.', 'groupId': 'OG004'}, {'value': '0.43', 'spread': '0.31', 'groupId': 'OG005'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Temperature was measured in degrees Celsius (°C).', 'unitOfMeasure': '°C', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Clinically Significant Physical Examination Abnormalities', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'categories': [{'measurements': [{'value': '23.8', 'groupId': 'OG000'}, {'value': '7.7', 'groupId': 'OG001'}, {'value': '11.6', 'groupId': 'OG002'}, {'value': '10.0', 'groupId': 'OG003'}, {'value': '9.3', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'At Screening, Week 12/Early Withdrawal Visit and the Safety Follow-Up Visit (20 weeks after the last dose)', 'description': 'The physical examination included general appearance; ear, nose, and throat; eyes, hair, and skin; respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental status.\n\nAny clinically significant abnormal findings during the study were captured as adverse events.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'Placebo (SS)', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W). Participants formed the Safety Set (SS).'}, {'id': 'OG001', 'title': 'Bimekizumab 64 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG002', 'title': 'Bimekizumab 160 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG004', 'title': 'Bimekizumab 320 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W. Participants formed the SS.'}, {'id': 'OG005', 'title': 'Bimekizumab 480 mg Q4W (SS)', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W. Participants formed the SS.'}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '40', 'groupId': 'OG003'}, {'value': '43', 'groupId': 'OG004'}, {'value': '43', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2.5', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '42', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2.6', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}, {'value': '41', 'groupId': 'OG002'}, {'value': '39', 'groupId': 'OG003'}, {'value': '41', 'groupId': 'OG004'}, {'value': '41', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '40', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '40', 'groupId': 'OG004'}, {'value': '40', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '39', 'groupId': 'OG000'}, {'value': '38', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '34', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}, {'value': '39', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'SFU', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}, {'value': '4', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '1', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}], 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline (Week 0), Week 2, Week 4, Week 6, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Percentages were based on the number of participants with a non-missing measurement for that variable at the visit.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The Safety Set (SS) consisted of all participants who received at least 1 dose of the IMP.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Placebo', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W).'}, {'id': 'FG001', 'title': 'Bimekizumab 64 mg Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W.'}, {'id': 'FG002', 'title': 'Bimekizumab 160 mg Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W.'}, {'id': 'FG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W.'}, {'id': 'FG004', 'title': 'Bimekizumab 320 mg Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W.'}, {'id': 'FG005', 'title': 'Bimekizumab 480 mg Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '42'}, {'groupId': 'FG001', 'numSubjects': '39'}, {'groupId': 'FG002', 'numSubjects': '43'}, {'groupId': 'FG003', 'numSubjects': '40'}, {'groupId': 'FG004', 'numSubjects': '43'}, {'groupId': 'FG005', 'numSubjects': '43'}]}, {'type': 'Completed Treatment Period', 'achievements': [{'groupId': 'FG000', 'numSubjects': '37'}, {'groupId': 'FG001', 'numSubjects': '36'}, {'groupId': 'FG002', 'numSubjects': '38'}, {'groupId': 'FG003', 'numSubjects': '34'}, {'groupId': 'FG004', 'numSubjects': '40'}, {'groupId': 'FG005', 'numSubjects': '39'}]}, {'type': 'Enrolled in Extension Study (PS0011)', 'achievements': [{'groupId': 'FG000', 'numSubjects': '38'}, {'groupId': 'FG001', 'numSubjects': '35'}, {'groupId': 'FG002', 'numSubjects': '39'}, {'groupId': 'FG003', 'numSubjects': '38'}, {'groupId': 'FG004', 'numSubjects': '42'}, {'groupId': 'FG005', 'numSubjects': '40'}]}, {'type': 'Entered Safety Follow-up Period', 'achievements': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '4'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '3'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '37'}, {'groupId': 'FG001', 'numSubjects': '36'}, {'groupId': 'FG002', 'numSubjects': '38'}, {'groupId': 'FG003', 'numSubjects': '34'}, {'groupId': 'FG004', 'numSubjects': '40'}, {'groupId': 'FG005', 'numSubjects': '39'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '5'}, {'groupId': 'FG003', 'numSubjects': '6'}, {'groupId': 'FG004', 'numSubjects': '3'}, {'groupId': 'FG005', 'numSubjects': '4'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '1'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}, {'type': 'Screening exclusion criteria met', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Lab withdrawal criterion met', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '2'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '1'}]}, {'type': 'Positive for Tuberculosis', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Subject positive for Hep B', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Patient moved abroad', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '0'}]}, {'type': 'Patient randomized by mistake', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '1'}]}]}], 'recruitmentDetails': 'The study started to enroll participants in August 2016 and concluded in July 2017.', 'preAssignmentDetails': 'The study included a 2-4 week Screening Period and a 12-week Treatment Period. Completed study was defined as completed the 12-week double-blind Treatment Period. After Treatment Period participants either enrolled in an extension study (PS0011) or entered a 20-week Safety Follow-Up Period.\n\nParticipant Flow refers to the Randomized Set.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '42', 'groupId': 'BG000'}, {'value': '39', 'groupId': 'BG001'}, {'value': '43', 'groupId': 'BG002'}, {'value': '40', 'groupId': 'BG003'}, {'value': '43', 'groupId': 'BG004'}, {'value': '43', 'groupId': 'BG005'}, {'value': '250', 'groupId': 'BG006'}]}], 'groups': [{'id': 'BG000', 'title': 'Placebo', 'description': 'Participants randomized to the placebo group, received a combination of several injections of placebo, subcutaneously every 4 weeks (Q4W).'}, {'id': 'BG001', 'title': 'Bimekizumab 64 mg Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 64 mg bimekizumab Q4W.'}, {'id': 'BG002', 'title': 'Bimekizumab 160 mg Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 160 mg bimekizumab Q4W.'}, {'id': 'BG003', 'title': 'Bimekizumab 160 mg w/ LD Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab loading dose at Baseline followed by 160 mg bimekizumab Q4W.'}, {'id': 'BG004', 'title': 'Bimekizumab 320 mg Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 320 mg bimekizumab Q4W.'}, {'id': 'BG005', 'title': 'Bimekizumab 480 mg Q4W', 'description': 'Participants were randomized to receive subcutaneous injections of 480 mg bimekizumab Q4W.'}, {'id': 'BG006', 'title': 'Total Title'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '2', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '39', 'groupId': 'BG000'}, {'value': '36', 'groupId': 'BG001'}, {'value': '40', 'groupId': 'BG002'}, {'value': '35', 'groupId': 'BG003'}, {'value': '39', 'groupId': 'BG004'}, {'value': '36', 'groupId': 'BG005'}, {'value': '225', 'groupId': 'BG006'}]}, {'title': '>=65 years', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '4', 'groupId': 'BG004'}, {'value': '5', 'groupId': 'BG005'}, {'value': '22', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '46.7', 'spread': '12.3', 'groupId': 'BG000'}, {'value': '44.2', 'spread': '13.8', 'groupId': 'BG001'}, {'value': '43.4', 'spread': '12.4', 'groupId': 'BG002'}, {'value': '46.5', 'spread': '15.2', 'groupId': 'BG003'}, {'value': '42.6', 'spread': '13.6', 'groupId': 'BG004'}, {'value': '42.9', 'spread': '15.2', 'groupId': 'BG005'}, {'value': '44.3', 'spread': '13.7', 'groupId': 'BG006'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '17', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}, {'value': '11', 'groupId': 'BG003'}, {'value': '15', 'groupId': 'BG004'}, {'value': '14', 'groupId': 'BG005'}, {'value': '87', 'groupId': 'BG006'}]}, {'title': 'Male', 'measurements': [{'value': '25', 'groupId': 'BG000'}, {'value': '20', 'groupId': 'BG001'}, {'value': '32', 'groupId': 'BG002'}, {'value': '29', 'groupId': 'BG003'}, {'value': '28', 'groupId': 'BG004'}, {'value': '29', 'groupId': 'BG005'}, {'value': '163', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'categories': [{'title': 'American Indian/Alaskan native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '1', 'groupId': 'BG005'}, {'value': '2', 'groupId': 'BG006'}]}, {'title': 'Asian', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '6', 'groupId': 'BG003'}, {'value': '3', 'groupId': 'BG004'}, {'value': '4', 'groupId': 'BG005'}, {'value': '22', 'groupId': 'BG006'}]}, {'title': 'Black', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '1', 'groupId': 'BG003'}, {'value': '1', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '3', 'groupId': 'BG006'}]}, {'title': 'White', 'measurements': [{'value': '39', 'groupId': 'BG000'}, {'value': '35', 'groupId': 'BG001'}, {'value': '39', 'groupId': 'BG002'}, {'value': '33', 'groupId': 'BG003'}, {'value': '39', 'groupId': 'BG004'}, {'value': '38', 'groupId': 'BG005'}, {'value': '223', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Baseline Characteristics refer to the Safety Set, which consisted of all participants who received at least 1 dose of the study medication.'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2016-07-18', 'size': 7620687, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2020-09-04T04:11', 'hasProtocol': True}, {'date': '2017-06-13', 'size': 3029460, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2020-09-04T04:14', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 250}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-08'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-07', 'dispFirstSubmitDate': '2018-06-08', 'completionDateStruct': {'date': '2017-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-07-14', 'studyFirstSubmitDate': '2016-09-14', 'dispFirstSubmitQcDate': '2018-06-08', 'resultsFirstSubmitDate': '2020-06-08', 'studyFirstSubmitQcDate': '2016-09-16', 'dispFirstPostDateStruct': {'date': '2018-06-12', 'type': 'ACTUAL'}, 'lastUpdatePostDateStruct': {'date': '2022-07-21', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-11-17', 'studyFirstPostDateStruct': {'date': '2016-09-19', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2020-11-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-06', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12', 'timeFrame': 'Week 12', 'description': "The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease."}], 'secondaryOutcomes': [{'measure': "Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 12", 'timeFrame': 'Week 12', 'description': "The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions."}, {'measure': "Percentage of Participants With Investigator's Global Assessment (IGA) (Clear or Almost Clear With at Least 2 Category Improvement From Baseline) Response at Week 8", 'timeFrame': 'Week 8', 'description': "The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions."}, {'measure': 'Percentage of Participants Achieving a 90% or Higher Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 8', 'timeFrame': 'Week 8', 'description': "The PASI90 response assessments are based on at least 90% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease."}, {'measure': 'Percentage of Participants Achieving a 75% or Higher Improvement in Psoriasis Area and Severity Index (PASI) Score at Week 12', 'timeFrame': 'Week 12', 'description': "The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline. This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved. Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease."}, {'measure': 'Percentage of Participants Achieving a 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 12', 'timeFrame': 'Week 12', 'description': "PASI correlates to the physician's assessment of psoriasis symptoms including redness of lesions, thickness of lesions, scaliness of lesions and extent of disease. Each parameter is graded from 0-4, 0 refers to no disease and 4 to severe involvement. The body is divided into 4 areas for scoring (head, arms, trunk to groin, legs to top of buttocks), and the final score ranges from 0-72. The PASI 100 response rate at Week 12 is measured as the percentage of participants who achieved 100% improvement from baseline PASI at Week 12."}, {'measure': 'Plasma Concentrations of Bimekizumab During the Study', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Bimekizumab plasma concentration was expressed in micrograms per milliliter (μg/mL).\n\nValues Below Limit of Quantification (BLQ) were replaced by the value of lower limit of quantification (LLOQ) divided by 2 = 0.075 μg/mL in the calculations of geometric mean and confidence intervals (CIs). Geometric mean was only calculated if at least two-thirds of the concentrations were quantified at the respective time point.'}, {'measure': 'Population PK (Apparent Total Clearance (CL/F)) of Bimekizumab', 'timeFrame': 'From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)', 'description': 'The data were presented as population estimates of CL/F. Given the sparse nature of PK sampling, CL/F cannot be estimated for each treatment group.\n\nIt was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.'}, {'measure': 'Population PK (Apparent Volume of Distribution (V/F)) of Bimekizumab', 'timeFrame': 'From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)', 'description': 'The data were presented as population estimates of V/F. Given the sparse nature of PK sampling, V/F cannot be estimated for each treatment group.\n\nIt was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.'}, {'measure': 'Concentration of Bimekizumab Leading to 50% of Maximum Effect (EC50)', 'timeFrame': 'From Baseline (Week 0) until Safety Follow-Up Visit (20 weeks after the last dose; Up to Week 28)', 'description': 'The data were presented as population estimates of EC50. EC50 was estimated based on all available data and cannot be derived for each treatment arm.\n\nIt was prespecified in the data analysis plan to combine doses to perform Population PK and PK/PD analysis based on a prior determination that the PK parameters are not dose-dependent.'}, {'measure': 'Percentage of Participants With a Positive Anti-bimekizumab Antibody (AbAb) Status Prior to Study Treatment', 'timeFrame': 'Baseline (Week 0)', 'description': 'Antibody positive status prior study treatment was defined as having an antibody level greater than (\\>) 28.5% at Baseline (Week 0).'}, {'measure': 'Percentage of Participants With an Overall Positive Anti-bimekizumab Antibody (AbAb) Status Following Study Treatment', 'timeFrame': 'From Week 4 until the Safety Follow-Up visit (20 weeks after the last dose; Up to Week 28)', 'description': 'Overall antibody positive was defined as having a value of \\> 28.5% at any time in the Treatment Period. The Treatment Period did not include Baseline/pretreatment samples.'}, {'measure': 'Percentage of Participants With at Least One Adverse Event (AE) During the Study', 'timeFrame': 'From Screening to End of Safety Follow-up (up to Week 32)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.'}, {'measure': 'Percentage of Participants With at Least One Adverse Event (AE) During the Study by Severity', 'timeFrame': 'From Screening to End of Safety Follow-up (up to Week 32)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Platelets)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Platelets was measured in number of platelets per liter (10\\^9/L).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration, Hemoglobin)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Erythrocytes mean corpuscular hemoglobin (HGB) concentration and hemoglobin were measured in grams per liter (g/L).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Hemoglobin (HGB))', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Erythrocytes mean corpuscular hemoglobin (HGB) was measured in picograms (pg).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes Mean Corpuscular Volume)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Erythrocytes mean corpuscular volume was measured in femtolitres (fL).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Erythrocytes)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Erythrocytes was measured in number of red blood cells per liter (10\\^12/L).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Hematocrit)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Hematocrit was measured in volume percentage (%) of red blood cells in blood.'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Hematology Parameters (Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Basophils, eosinophils, leukocytes, lymphocytes, monocytes and neutrophils were measured in number of white blood cells per liter (10\\^9/L).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Calcium, Chloride, Potassium, Magnesium, Sodium, Urea Nitrogen, Cholesterol, Glucose)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Calcium, chloride, potassium, magnesium, sodium, urea nitrogen, cholesterol and glucose were measured in millimoles per liter (mmol/L).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Lactate Dehydrogenase, Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Lactate dehydrogenase, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase were measured in units per liter (U/L).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (Creatinine, Bilirubin)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Creatinine and bilirubin were measured in micromols per liter (μmol/L).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Biochemistry Parameters (C Reactive Protein)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'C Reactive Protein was measured in milligrams per liters (mg/L).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Urinalysis Parameters (pH)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Urine pH was measured on a pH scale.'}, {'measure': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Leukocyte Esterase)', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.'}, {'measure': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Nitrite)', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.'}, {'measure': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Occult Blood)', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.'}, {'measure': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Urine Glucose)', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.'}, {'measure': 'Percentage of Participants Who Shifted From Baseline Until Week 12 in Urinalysis Parameters (Albumin)', 'timeFrame': 'From Baseline (Week 0) until Week 12', 'description': 'Percentages were based on the number of participants with non-missing urinalysis results at Baseline and at Week 12.'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Vital Signs (Blood Pressure)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Blood pressure was measured in millimeters of mercury (mmHg).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Vital Signs (Pulse Rate)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Pulse rate was measured in beats per minute (beats/min).'}, {'measure': 'Change From Baseline Until Safety Follow-up Visit in Vital Signs (Temperature)', 'timeFrame': 'Baseline (Week 0), Week 1, Week 2, Week 4, Week 6, Week 8, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Temperature was measured in degrees Celsius (°C).'}, {'measure': 'Percentage of Participants With Clinically Significant Physical Examination Abnormalities', 'timeFrame': 'At Screening, Week 12/Early Withdrawal Visit and the Safety Follow-Up Visit (20 weeks after the last dose)', 'description': 'The physical examination included general appearance; ear, nose, and throat; eyes, hair, and skin; respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental status.\n\nAny clinically significant abnormal findings during the study were captured as adverse events.'}, {'measure': 'Percentage of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings', 'timeFrame': 'Baseline (Week 0), Week 2, Week 4, Week 6, Week 12, and Safety Follow-Up visit (20 weeks after the last dose)', 'description': 'Percentages were based on the number of participants with a non-missing measurement for that variable at the visit.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Psoriasis', 'Chronic Plaque Psoriasis', 'Bimekizumab'], 'conditions': ['Chronic Plaque Psoriasis']}, 'referencesModule': {'references': [{'pmid': '35544084', 'type': 'RESULT', 'citation': 'Gordon KB, Langley RG, Warren RB, Okubo Y, Stein Gold L, Merola JF, Peterson L, Wixted K, Cross N, Deherder D, Thaci D. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185.'}]}, 'descriptionModule': {'briefSummary': 'This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to investigate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of Bimekizumab compared with placebo in adult subjects with moderate to severe chronic plaque psoriasis in order to guide the selection of doses and clinical indices in the Phase 3 development program.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Subject has provided informed consent\n* Chronic plaque psoriasis for at least 6 months prior to Screening\n* PASI (Psoriasis Area and Severity Index) \\>=12 and BSA (body surface area) \\>=10% and IGA (Investigator's Global Assessment) score 3 or greater on a 5-point scale\n* Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy\n* Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug\n* Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication\n\nExclusion Criteria:\n\n* Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced psoriasis\n* Subject has any severe, progressive and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, gastrointestinal or neurological disease\n* Subject has any significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol\n* Subject taking prohibited psoriatic medications\n* Subject receiving any live vaccines within 8 weeks prior to the Baseline and subjects receiving Bacillus Calmette-Guerin (BCG) vaccination within 1 year prior to study drug administration\n* Subject has previously received treatment with any anti-interleukin-17 (anti-IL-17) therapy or has been exposed to more than 1 biological response modifier (limited to anti-tumor necrosis factor (TNF) or IL-12/23) for psoriatic arthritis or psoriasis prior to the Baseline\n* Subject has any current sign or symptom that may indicate an active infection (except for common cold)"}, 'identificationModule': {'nctId': 'NCT02905006', 'acronym': 'BE ABLE 1', 'briefTitle': 'Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis', 'organization': {'class': 'INDUSTRY', 'fullName': 'UCB Pharma'}, 'officialTitle': 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis', 'orgStudyIdInfo': {'id': 'PS0010'}, 'secondaryIdInfos': [{'id': '2016-001891-31', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'interventionNames': ['Other: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Bimekizumab dosing regimen 1', 'interventionNames': ['Drug: Bimekizumab', 'Other: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Bimekizumab dosing regimen 2', 'interventionNames': ['Drug: Bimekizumab', 'Other: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Bimekizumab dosing regimen 3', 'interventionNames': ['Drug: Bimekizumab', 'Other: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Bimekizumab dosing regimen 4', 'interventionNames': ['Drug: Bimekizumab', 'Other: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Bimekizumab dosing regimen 5', 'interventionNames': ['Drug: Bimekizumab']}], 'interventions': [{'name': 'Bimekizumab', 'type': 'DRUG', 'otherNames': ['UCB4940'], 'description': 'Subjects will be randomized to receive a combination of injections of Bimekizumab.', 'armGroupLabels': ['Bimekizumab dosing regimen 1', 'Bimekizumab dosing regimen 2', 'Bimekizumab dosing regimen 3', 'Bimekizumab dosing regimen 4', 'Bimekizumab dosing regimen 5']}, {'name': 'Placebo', 'type': 'OTHER', 'description': 'Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.', 'armGroupLabels': ['Bimekizumab dosing regimen 1', 'Bimekizumab dosing regimen 2', 'Bimekizumab dosing regimen 3', 'Bimekizumab dosing regimen 4', 'Placebo']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Fremont', 'state': 'California', 'country': 'United States', 'facility': 'Ps0010 711', 'geoPoint': {'lat': 37.54827, 'lon': -121.98857}}, {'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Ps0010 708', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'Ps0010 706', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'city': 'West Des Moines', 'state': 'Iowa', 'country': 'United States', 'facility': 'Ps0010 704', 'geoPoint': {'lat': 41.57721, 'lon': -93.71133}}, {'city': 'Rochester', 'state': 'New York', 'country': 'United States', 'facility': 'Ps0010 718', 'geoPoint': {'lat': 43.15478, 'lon': -77.61556}}, {'city': 'Wilmington', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Ps0010 738', 'geoPoint': {'lat': 34.23556, 'lon': -77.94604}}, {'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'Ps0010 736', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Ps0010 712', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Ps0010 733', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Ps0010 702', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Ps0010 709', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'city': 'Surrey', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Ps0010 203', 'geoPoint': {'lat': 49.10635, 'lon': -122.82509}}, {'city': 'Hamilton', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Ps0010 204', 'geoPoint': {'lat': 43.25011, 'lon': -79.84963}}, {'city': 'North Bay', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Ps0010 201', 'geoPoint': {'lat': 46.3168, 'lon': -79.46633}}, {'city': 'Peterborough', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Ps0010 206', 'geoPoint': {'lat': 44.30012, 'lon': -78.31623}}, {'city': 'Waterloo', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Ps0010 205', 'geoPoint': {'lat': 43.4668, 'lon': -80.51639}}, {'city': 'Québec', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Ps0010 214', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}, {'city': 'Edmonton', 'country': 'Canada', 'facility': 'Ps0010 209', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'city': 'Québec', 'country': 'Canada', 'facility': 'Ps0010 214', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}, {'city': 'Ostrava Poruba', 'country': 'Czechia', 'facility': 'Ps0010 300'}, {'city': 'Pardubice', 'country': 'Czechia', 'facility': 'Ps0010 303', 'geoPoint': {'lat': 50.04075, 'lon': 15.77659}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'Ps0010 301', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Prague', 'country': 'Czechia', 'facility': 'Ps0010 304', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'city': 'Kecskemét', 'country': 'Hungary', 'facility': 'Ps0010 404', 'geoPoint': {'lat': 46.90618, 'lon': 19.69128}}, {'city': 'Orosháza', 'country': 'Hungary', 'facility': 'Ps0010 400', 'geoPoint': {'lat': 46.56667, 'lon': 20.66667}}, {'city': 'Szekszárd', 'country': 'Hungary', 'facility': 'Ps0010 405', 'geoPoint': {'lat': 46.34723, 'lon': 18.71189}}, {'city': 'Nagoya', 'country': 'Japan', 'facility': 'Ps0010 502', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'city': 'Shinaga Wa-ku', 'country': 'Japan', 'facility': 'Ps0010 501'}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Ps0010 503', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Tokyo', 'country': 'Japan', 'facility': 'Ps0010 504', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}, {'city': 'Bialystok', 'country': 'Poland', 'facility': 'Ps0010 600', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'city': 'Bialystok', 'country': 'Poland', 'facility': 'Ps0010 611', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'city': 'Gdansk', 'country': 'Poland', 'facility': 'Ps0010 605', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'city': 'Gdynia', 'country': 'Poland', 'facility': 'Ps0010 610', 'geoPoint': {'lat': 54.51889, 'lon': 18.53188}}, {'city': 'Kielce', 'country': 'Poland', 'facility': 'Ps0010 604', 'geoPoint': {'lat': 50.87033, 'lon': 20.62752}}, {'city': 'Krakow', 'country': 'Poland', 'facility': 'Ps0010 608', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'city': 'Lublin', 'country': 'Poland', 'facility': 'Ps0010 606', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'city': 'Podlaski', 'country': 'Poland', 'facility': 'Ps0010 603', 'geoPoint': {'lat': 53.09312, 'lon': 17.80653}}, {'city': 'Warsaw', 'country': 'Poland', 'facility': 'Ps0010 607', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Ps0010 601', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Ps0010 609', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}], 'overallOfficials': [{'name': 'UCB Cares', 'role': 'STUDY_DIRECTOR', 'affiliation': '+1 844 599 2273 (UCB)'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'UCB Biopharma S.P.R.L.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Parexel', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}